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Abbreviations 
 
 
ATP  Adenosine triphosphate 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate 
CK-7  Cytokeratin 7 
CLSM  Confocal laser scanning microscopy 
CNT  Carbon nanotubes 
DAPI  4',6-diamidino-2-phenylindole 
DCF  2’,7’-dichlorofluorescein 
DD  Double distilled  
DLS  Dynamic light scattering 
DMSO Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
EDTA  Ethylenediaminetetraacetic acid 
EGF  Epithelial growth factor 
ELISA  Enzyme-linked immunosorbent assay 
ENM  Engineered nanomaterial 
EPR  Enhanced permeability and retention 
F  Fetal 
FACS  Fluorescence-activated cell sorting 
FC   Fetal capillary 
FCS  Fetal calf serum 
hCG  Human chorionic gonadotropin 
HE  Hematoxylin and eosin 
HLA  Human leukocyte antigen 
hPL  Human placental lactogen 
hr  Hour 
ICP-MS Inductively coupled plasma mass spectrometry 
Ig  Immunoglobulin 
IL  Interleukin 
LPS  Lipopolysaccharide 
M  Maternal 
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MB  Maternal blood space 
MHC  Major histocompatibility complex 
MRI  Magnetic resonance imaging 
MTS  3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-
2H-tetrazolium 
MV  Microvilli 
MWCNT Multi-walled carbon nanotubes 
NP  Nanoparticle 
PBS  Phosphate buffered saline 
PEG  Polyethylene glycol 
PFA  Paraformaldehyde 
PLGA  Poly(lactic-co-glycolic acid) 
PM  Perfusion medium 
PMA  Phorbol-12-myristat-13-acetat 
ppm  Parts per million 
PS  Polystyrene beads 
RES  Reticuloendothelial system 
ROS  Reactive oxygen species 
SD  Standard deviation 
SDS  Sodium dodecyl sulfate 
Sin-1  3-Morpholinosydnonimine 
SPION Superparamagnetic iron oxide nanoparticle 
ST  Syncytiotrophoblast 
TEM  Transmission electron microscopy 
TGF-β  Transforming growth factor beta 
TNF-α  Tumor necrosis factor alpha 
QSAR  Quantitative structure-activity relationship 
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1. SUMMARY 
 
Today, nanotechnology is part of our everyday life. Engineered nanomaterials (ENM) have 
several novel specific properties compared to the respective bulk material. These 
characteristics make them highly attractive for many industries. Although there are already 
numerous consumer products containing a broad variety of ENMs, the field of nanotechnology 
is still growing. Particularly, applications of ENMs in medicine have been established or are 
currently under development. However, many studies showed that nanomaterials can have 
negative effects on human health. Besides the commonly investigated primary biological 
barriers such as skin, lung and intestine, exposure to ENMs at internal barriers gets 
increasingly important. Especially medical ENMs are intravenously injected and can directly 
enter the blood stream. One transient, but highly important internal barrier is the human 
placenta, which regulates the fetal nutrient supply and protects the fetus from harmful 
endogenous and exogenous substances. It has been shown that different ENMs can cross the 
placental barrier in humans and rodents and even cause pregnancy complications in mice. 
However, the placenta is the most species-specific mammalian organ and results from placental 
transport studies in rodents cannot simply be translated to humans. ENMs also offer the 
opportunity to develop new therapeutic strategies to treat specifically the pregnant mother, 
placental abnormalities or the fetus. Though, for the development of such nanomedical 
applications, an extensive knowledge about the physicochemical properties of ENMs, which 
are responsible for their placental transfer, and the transport mechanisms of ENMs is a 
prerequisite.  
In the first part of this thesis, we established and improved the ex vivo human placental 
perfusion model. The placentas were obtained after informed consent of the pregnant women 
and only from uncomplicated term pregnancies after caesarean delivery. The fetal and maternal 
vessels of an intact cotyledon were cannulated and perfused for six hours. This perfusion 
model was chosen, because it delivers reliable, comparable and physiological relevant results 
about placental transfer of chemical compounds as well as ENMs.  
In the second part of this thesis, we examined the mechanisms underlying ENM transport 
across the human placenta using the ex vivo human placental perfusion model and fluorescently 
labeled polystyrene particles with different sizes and surface modifications (plain and 
carboxylate-modified) as model particles. The placental transfer of carboxylate-modified 
polystyrene beads was significantly lower compared to plain polystyrene beads. These results 
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indicate that not only size, but also the surface modifications and charge are determinants of 
ENM transport across the human placenta. However, to corroborate this finding further studies 
with a broader variety of surface functionalized nanoparticles are required. Bidirectional 
transfer studies revealed an increased translocation of polystyrene beads from the fetal to 
maternal direction compared to the transport from the maternal to the fetal circulation. Based 
on these results, a passive placental transport mechanism of polystyrene particles could be 
excluded. We suggest that energy-dependent mechanisms in the syncytiotrophoblast layer of 
the human placenta contribute predominantly to the transfer of polystyrene particles.  
In the third part of this thesis, we presented some common challenges, which emerged during 
evaluation and selection of polystyrene nanoparticles with different physicochemical 
properties. We showed that a thorough particle characterization comprising size distribution 
analysis, detection of the chemical groups on functionalized polystyrene beads and assessment 
of dye elution in the appropriate biological environment are indispensable in order to obtain 
meaningful results from placental transfer studies.  
In the fourth part of this thesis, we elucidated if the cellular responses after ENM exposure 
differ between BeWo cells, a cell line derived from a malignant gestational choriocarcinoma, 
and primary human cytotrophoblasts. BeWo cells are frequently used in placental in vitro 
models, but primary cytotrophoblasts isolated from the human term placenta are 
physiologically more relevant. This comparison is required in order to evaluate the suitability 
of these cell types for the development of advanced in vitro models for the human placenta. 
Due to the limitations of the ex vivo human placental perfusion model e.g. constrained 
feasibility of high throughput screenings of many different ENMs as well as of long-term 
exposure studies, in vitro models are necessary. This study is still ongoing, but preliminary 
results demonstrated that the isolation of primary human cytotrophoblasts is technically 
challenging and the yield quite low. Though, these cells might be only suitable for in vitro 
models such as three-dimensional microtissues or microfluidic chips, where a low number of 
cells is required.     
Overall, the results presented in this thesis are essential for the understanding of the 
translocation mechanisms of ENMs across the placenta barrier. Furthermore, these findings 
will be important for organ toxicology, reproductive toxicology (teratogenicity) as well as for 
pharmaceutical engineering of new drug carriers.  
2. Introduction 
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2. INTRODUCTION 
 
2.1 Nanoparticles 
 
2.1.1 Definition 
According to the recommendation of the European Union commission from the 18th October 
2011, nanomaterials are defined as materials containing 50 % or more particles in the number 
size distribution with at least one external dimension in a size range between 1 and 100 nm. 
Nanoparticles (NPs) are nanomaterials with all three external dimensions in the nanoscale (see 
also ISO/TS 27687:2008, International Organization for Standardization). This classification is 
based on observations that materials in the ‘nano’ size range show special properties, which are 
substantially different from the bulk material. The high surface-to-volume ratio of NPs leads to 
a massively higher chemical reactivity and NPs also show size-dependent quantum effects e.g. 
color and luminescence of quantum dots (Goesmann and Feldmann, 2010). There is 
controversial discussion about the strict definition of NPs (Auffan et al., 2009, Goesmann and 
Feldmann, 2010). However, in the field of biology and toxicology it is widely known that also 
larger particles can induce similar responses in biological systems as NPs. Therefore, the 
definition of NPs should be considered with caution (Krug and Wick, 2011). In general NPs 
can be further discriminated by their origin. Naturally occurring NPs e.g. ultrafine dust 
particles are released during volcano eruptions or forest fires, unintentionally produced NPs are 
mainly liberated through distinct combustion processes and intentionally produced NPs are 
specifically engineered for plenty industrial applications. The latter nanomaterials including 
nanoparticles, nanofibers and nanoplates, are often summarized under the term engineered 
nanomaterials (ENMs). 
 
2.1.2 Opportunities of nanoparticles  
A great number of industrial products containing ENMs are already on the market and it is 
anticipated that this number will even increase in the future (Maynard, 2007, Service, 2004). 
Due to the novel and exciting properties of ENMs they are used in many various areas such as 
energy production and storage, construction, computer, car, packaging, textile and cosmetics 
industries (Figure 1). For example titanium dioxide nanoparticles are used in wood 
preservatives, textile fibers and sunscreens due to their high resistance to ultraviolet light 
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(Figure 1A). The small size of ENMs allows them to enter cells more easily than the bulk 
material. This characteristic makes ENMs especially interesting for medical purposes.  
 
 
Figure 1: TEM micrographs and potential applications of metal oxide nanoparticles: titanium dioxide in 
cosmetics (A), silicon dioxide in wood preservatives or paints (B), iron oxide nanoparticles as contrast agents in 
MRI (C) and zinc oxide in solar cells (D). Reprinted with permission from (Wick et al., 2014). MRI image in (C) 
was adapted with permission from (Mahmoudi et al., 2011), Copyright © 2011, American Chemical Society. 
 
Nanomedicine is a fast growing area and essentially means the application of nanotechnology 
concepts in medicine. Nanomedical ENMs are developed for diagnostics, imaging as well as 
for therapeutic use especially in cancer treatment (Riehemann et al., 2009).  For example 
superparamagnetic iron oxide nanoparticles (SPIONs) and silica nanovectors can be used in 
diverse biomedical applications such as contrast agents in magnetic resonance imaging (MRI), 
cancer therapy, cell tracking and as drug delivery vehicles (nanocarriers) (Gupta and Gupta, 
2005, Tang et al., 2012) (Figure 1C). Most of these ENMs belong to the first generation of 
nanocarriers and utilize the EPR (enhanced permeability and retention) effect in order to reach 
their targets, which are mainly tumor cells. In contrast, nanocarriers of the second generation 
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contain a certain receptor ligand or antibody on their surface, which directs them specifically to 
the target cells. Often they also comprise a mechanism for drug release after reaching the target 
cell, e.g. pH-sensitive polymers or SPIONs activated by an external magnetic field. In addition, 
a third generation of nanocarriers are currently under development and are designed with 
specific abilities to efficiently overcome biological barriers in order to further enhance the drug 
concentration in the diseased tissue. Furthermore, nanotechnology contributes significantly to 
the progression in the field of personalized medicine by providing new tools for the 
development of biosensors as well as micro- and nanoarrays for diagnostic applications 
(Riehemann et al., 2009).  
ENMs also offer various possibilities in the field of obstetrics. Target-oriented therapy could 
be used to either specifically treat fetal diseases or placental dysfunctions. Moreover, the 
number of women needing medication during pregnancy is strongly growing (Andrade et al., 
2004, Gendron et al., 2009, Mitchell et al., 2011). In many cases drugs have to be prescribed 
despite of their known off-target effects and the subsequent potentially harmful influence on 
the developing fetus. Therefore, nanocarriers without the ability to be transferred to the fetus 
would be of great interest and solve the problem of teratogenicity (capability of many drugs to 
cause birth defects). 
 
2.1.3 Uptake of nanoparticles  
The small size of ENMs enables them to utilize a broad variety of uptake mechanisms into 
cells (Treuel et al., 2013, Kettiger et al., 2013, Zhu et al., 2013) (Figure 2). However, the main 
uptake routes involve vesicular transport. Specialized immune cells (macrophages, monocytes, 
neutrophils, dendritic cells) engulf larger particles (> 500 nm) via phagocytosis. This process is 
triggered by different receptors specific for distinct ligands, which are predominantly expressed 
on pathogens or stressed cells (Aderem and Underhill, 1999). It has been shown that different 
ENMs are taken up via phagocytosis, even if they have a diameter below 500 nm (Franca et al., 
2011, Krpetic et al., 2010, Lunov et al., 2011). Pinocytosis is another mechanism reported to 
play a role in ENM uptake in non-phagocytic cells (Jin et al., 2009, Xia et al., 2008). 
Pinocytosis comprises macropinocytosis, clathrin- and caveolin-mediated endocytosis as well 
as clathrin/caveolin-independent endocytosis. Particles > 1 μm and some viruses are commonly 
ingested unspecifically via macropinocytosis, whereas smaller particles usually utilize other 
endocytosis pathways (Conner and Schmid, 2003, Mercer and Helenius, 2009, Kettiger et al., 
2013). Clathrin-mediated endocytosis is either triggered by receptor binding or by nonspecific 
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adsorption of cationic ENMs to the negatively charged plasma membrane. ENMs with an 
average size between 120 – 150 nm and a maximum of 200 nm are internalized via clathrin-
dependent endocytosis (Chithrani et al., 2006, McMahon and Boucrot, 2011, Rejman et al., 
2004). Caveolin-coated vesicles are usually in a size range between 60 – 80 nm (Parton and 
Simons, 2007). However, it has been observed that smaller ENMs (20 – 40 nm) are also able to 
use caveolin-mediated endocytosis and that their uptake is even more efficient compared to 
larger ENMs (Gratton et al., 2008, Wang et al., 2009). Of note, many caveolin- and clathrin-
independent endocytosis mechanisms exist and it is discussed that particles with a diameter of 
about 90 nm or larger get access into cells via such pathways (Mayor and Pagano, 2007). Most 
vesicles enter the endosomal/lysosomal trafficking route, but transcytosis is also possible 
especially in polarized barrier cells (Conner and Schmid, 2003). Additionally, some few 
studies reported a passive uptake pathway of ENMs in erythrocytes, which lack conventional 
endocytosis mechanisms (Rothen-Rutishauser et al., 2006, Wang et al., 2012). These findings 
demonstrate that different cell types can interact differently with the same ENMs. 
 
 
Figure 2: Schematic illustration of potential cellular uptake mechanisms for ENMs. Adapted with permission 
from (Zhu et al., 2013), Copyright © 2013, American Chemical Society.  
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Besides cellular mechanisms, the characteristics of ENMs are also major determinants of 
cellular uptake. ENMs with a diameter of about 50 nm are internalized faster and more 
efficiently than smaller (15 – 30 nm) or larger (70 – 240 nm) particles (Chithrani et al., 2006, 
Lu et al., 2009). In addition, ENMs with a size of 30 – 50 nm have a greater potential to 
interact with diverse cellular receptors and induce receptor-mediated endocytosis (Kettiger et 
al., 2013, Lu et al., 2009). The shape of ENMs also influences cellular uptake. Spherical ENMs 
enter cells more easily compared to elongated ENMs such as carbon nanotubes (Champion et 
al., 2007, Ferrari, 2008). Surface properties (surface charge and surface modifications) of 
ENMs are also important factors. In most cells cationic ENMs are more efficiently taken up 
due to their strong interaction with the anionic plasma membrane and subsequent induction of 
adsorption-triggered endocytosis (Qiu et al., 2010, Xia et al., 2008). 
After contact with a biological environment ENMs acquire a protein corona dependent on their 
size, shape, chemistry and surface characteristics. Proteins and other biomolecules contained in 
plasma or other biological fluids are adsorbed to the surface of ENMs. This protein corona 
leads to an altered hydrodynamic diameter and net charge of ENMs. Consequently, these 
adsorbed proteins can considerably change the mechanisms of cellular uptake (Hirsch et al., 
2013, Lundqvist et al., 2008, Monopoli et al., 2011).  
 
2.1.4 Safety of nanoparticles 
Besides the great opportunities for various new applications of nanotechnology, the potential 
risks of ENMs on human health should not be neglected. Risk assessment of ENMs comprises 
the evaluation of exposure as well as the identification and characterization of the hazard. 
Exposure relates to the probability to be exposed to a critical dose of ENMs in the 
environment, while hazard refers to the biological effect of ENMs (Krug and Wick, 2011). To 
cause adverse effects ENMs have to cross certain primary biological barriers (Ferin et al., 
1992), except if they are administered directly by intravenous injection. The role of biological 
barriers is discussed in the following section 2.2.1. This section is focused on the exposure 
scenario of nanomedical ENMs. When ENMs enter the blood stream, they will adsorb proteins 
or they can also be opsonized by other biomolecules, which results in a rather fast clearance by 
the phagocytes of the reticuloendothelial system (RES) (Garnett and Kallinteri, 2006). ENMs 
with a diameter between 5 – 10 nm are eliminated by glomerular filtration in the kidney (Choi 
et al., 2007). All particles, which escape these protecting mechanisms, predominantly 
accumulate in the liver, lung and spleen (Semmler-Behnke et al., 2008, Xie et al., 2010). Like 
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ENM uptake, biodistribution of ENMs is dependent on the physicochemical characteristics 
(Kunzmann et al., 2011, Nel et al., 2009). For example hydrophobic ENMs are faster removed 
from the blood circulation by cells of the RES than hydrophilic ENMs (Duan and Li, 2013, 
Gessner et al., 2000, Shah et al., 2012). To prolong the circulation time, many medical ENMs 
are coated with polyethylene glycol (PEG), which reduces the opsonization with biomolecules 
and thus diminishes or even prevents the recognition and clearance by the RES (Shah et al., 
2012, Owens and Peppas, 2006).  
Many epidemiological, in vitro and in vivo (in animal models) studies have been performed 
during the last years to analyze the toxicity and hazard of ENMs and revealed that ENMs can 
have several adverse effects on health (Oberdorster et al., 2005). The skin, respiratory, 
cardiovascular, nervous and reproductive system could be negatively affected by ENMs 
(Pietroiusti, 2012). On a cellular level it has been observed that ENMs may cause cytotoxicity, 
inflammation, genotoxicity and oxidative stress dependent on their physicochemical properties 
(Nel et al., 2006, Nel et al., 2009). For example carbon nanotubes longer than 20 μm and with a 
diameter less than 3 μm cannot be internalized by phagocytes and induce inflammation, 
fibrosis or even cancer in the lung (Oberdorster, 2002, Donaldson et al., 2013).  
Few years ago, three principles about nanotoxicology were published in order to elucidate if 
ENMs possess unique features leading to different interactions at the nano-bio interface 
compared to their bulk material (Krug and Wick, 2011, Nel et al., 2006). The transport 
principle was already discussed on the previous section and is based on the small size of 
ENMs, which enables them to use different uptake pathways. Many metal oxide nanoparticles 
are slowly dissolving and therefore the ionic forms of the metal can be found. An imbalance in 
cellular ion balance has fatal consequences. Therefore, cellular ion transport is strongly 
regulated. However, ENMs can infiltrate cells via diverse pathways and release ions once they 
are inside the cells inducing severe cytotoxic effects. This effect is termed ‘Trojan Horse 
Mechanism’ and is very specific for ENMs (Deng et al., 2009, George et al., 2010, Limbach et 
al., 2007, Park et al., 2010). The surface principle describes the consequences of the high 
surface-to-volume ratio of ENMs. If the same mass of differently sized ENMs is taken, the 
specific surface and the particle number are significantly higher for smaller ENMs. This makes 
more chemical reactive groups available on the surface and offers more possibilities for nano-
bio interactions (Nel et al., 2006). The material principle refers to the many different materials 
from which ENMs can be composed of. Different chemistry can induce distinct effects in cells 
(Brunner et al., 2006, Gojova et al., 2007). It becomes evident that nanomaterials have unique 
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properties and a different behavior than the bulk material, which requires that the toxicological 
effects of ENMs in biological systems have to be studied in a systematic manner. This study 
domain is known as Nanotoxicology.  
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2.2 The human placenta 
 
2.2.1 Biological barriers 
Biological barriers build the border between different compartments inside the body as well as 
between an organism and its environment. They strongly regulate the exchange of diverse 
substances such as nutrients, gases or water between these interfaces. Depending on their 
specific function biological barriers consist of several layers and different cell types. In humans 
the skin, the lung, the intestine and the olfactory epithelium are barriers, which either directly 
face the environment e.g. the air or are in contact with fluids containing exogenous substances 
in case of the intestine. If a substance is able to cross one of these primary barriers and enter 
the blood stream, the endothelium of the capillaries constitutes the next hurdle before it can 
reach other internal organs. The endothelium in most tissues is continuous with strong tight 
junctions and a close connection to the basement membrane (Mehta and Malik, 2006). Though, 
in some specialized organs such as the liver and the spleen the endothelium is fenestrated and 
allows also transfer of larger molecules, proteins or particles. In contrast, special internal 
barriers like the placenta, the blood-brain and blood-retinal barrier are required to protect 
organs or tissues, which are particularly susceptible to potentially toxic exogenous substances 
and to disturbance of the homeostasis. They are composed of highly specialized cells, which 
regulate the transport of nutrients, gases and xenobiotics. The placenta is a barrier with a 
unique physiology and structural complexity (Huppertz and Gauster, 2011). The placenta is 
probably the most important barrier at all due to its function to feed and protect the sensitive 
developing fetus. The consequences of placental dysfunctions are absolutely detrimental for the 
fetus.  
  
2.2.2 Structure and functions of the placenta 
Human placental development and structure 
The placenta is mainly derived from fetal tissue. Four days after fertilization the morula 
(developmental embryonic stage with 16 cells) develops into the blastocyst, which consists of 
an outer cell layer and a fluid filled cavity with an inner cell mass. The embryo arises from the 
inner cell mass whereas the placenta originates from the outer trophoblast cells. Six days after 
gestation, the blastocyst begins to attach to the endometrium (the inner layer of the maternal 
uterus) and placenta development is initiated (Verma and Verma, 2013). The trophoblast cells 
in the outer blastocyst layer give rise to two different trophoblast populations, the 
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mononucleated cytotrophoblast and the multinucleated syncytiotrophoblast (Benirschke, 2012). 
These cell types are the basis of the first primary placental villi, which start to invade the uterus 
wall. The syncytiotrophoblast is formed by fusion of several trophoblasts and builds the outer 
layer of the villous placental structure facing the maternal side, while the mononucleated 
cytotrophoblasts line the inner surface of the villi. It has been shown that the development and 
differentiation of the syncytiotrophoblast is mainly driven by cyclic adenosine monophosphate 
(cAMP), epidermal growth factor (EGF) and human chorionic gonadotropin (hCG) (Maruo et 
al., 1987, Ringler et al., 1989, Shi et al., 1993). At the tip of the invading villi some 
cytotrophoblasts differentiate further into the invasive extravillous trophoblasts. These cells 
infiltrate all layers of the uterus as well as the uterine arteries leading to the formation of 
lacunas filled with maternal blood. Later these blood filled sinuses develop into the huge 
intervillous space, where the maternal blood enters via the spiral arteries and leaves through 
endometrial veins. The human placenta has a hemochorial structure, which means that the fetal 
villi extend into the intervillous space and the maternal blood has direct contact with the fetal 
syncytiotrophoblast (Figure 3). Subsequently, the primary villi mature into secondary villi by 
acquiring an inner core filled with extraembryonic mesoderm. After three weeks of gestation 
these mesenchymal cells give rise to the fetal capillaries and the connective tissue containing 
fibroblasts and macrophages (Hofbauer cells) (Figure 3). The fetal capillaries of these tertiary 
villi are successively connected to the vessels of the umbilical cord.  
 
 
Figure 3: Illustration of the placental structure in humans. Left panel depict an overview of one cotyledon, the 
middle and right panels demonstrate the structure of the cellular barrier during early (first trimester) and late (third 
trimester) pregnancy. Graph on the left was modified from (BIOG, 2013). Magnified illustrations on the right 
were adapted by permission from Macmillan Publishers Ltd: Nature Reviews Genetics (Rossant and Cross, 2001), 
Copyright © 2001. 
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During the first trimester (week 1 to 12 of gestation) the fetal-maternal barrier comprises the 
endothelial cells of the fetal capillaries embedded in the connective tissue and two continuous 
layers of trophoblast cells, the inner layer of cytotrophoblasts and the multinucleated 
syncytiotrophoblast (Figure 3). During progression of pregnancy the inner cytotrophoblast 
layer gets thinner, the number of fetal capillaries rises and the capillaries move closer to the 
syncytiotrophoblast. In the third trimester (week 28 of gestation until birth) only few single 
mononucleated cytotrophoblasts are left (Figure 3, Figure 4) (Juch et al., 2013, Syme et al., 
2004, Verma and Verma, 2013). Moreover, maternal blood flow is marginal until week 10 – 11 
post conception in order to maintain hypoxic conditions in the placenta. During early 
development, the embryo is highly vulnerable for oxidative stress and increase in placental 
oxygen pressure is associated with severe pregnancy complications such as spontaneous 
abortion, intrauterine growth restriction or preeclampsia (Burton and Jauniaux, 2011, Burton et 
al., 2009). To prevent substantial maternal blood flow in this early phase, the spiral arteries are 
plugged by extravillous cytotrophoblast cells (Duc-Goiran et al., 1999). Hence, maternal blood 
cells have to pass this cellular filter via intercellular channels to access the intervillous space. 
Successively, these cellular plugs vanish, the spiral arteries gain a direct connection to the 
intervillous space and perfusion with maternal blood is completely established at the end of the 
first trimester (Burton et al., 1999). Overall, these structural changes of the placenta during 
development, lead to an improved exchange of nutrients between the mother and the fetus 
(Verma and Verma, 2013). The fetal side of the term placenta with all fetal vessels emanating 
from the umbilical cord is named the chorionic plate or chorion. The part of the maternal 
endometrium contributing to placentation is called the decidua basalis. From the decidua 
several septa divide the placenta in different functional units, the cotyledons, of which each 
includes one fetal villous tree. At term the placenta consist of 20 - 40 cotyledons with a total 
exchange area of about 13 m
2
 (Larsen et al., 1995, Syme et al., 2004) (Figure 5). This large 
surface is generated through the extensive division of the fetal villi in a tree-like structure and 
through the microvillous structure of the syncytiotrophoblast at the brush border membrane, 
which faces the maternal blood sinus (Figure 4D). The membrane of syncytiotrophoblast 
touching the villous stroma is the basal membrane. 
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Figure 4: (A + B) Images from light microscopic analyses of human placental tissue at term after 
hematoxylin/eosin (HE) staining. The samples were prepared and analyzed in collaboration with the Department 
of Pathology at the Cantonal Hospital in St. Gallen. (C + D) TEM micrographs demonstrate the cellular structure 
of human placental tissue at term. The samples were prepared and analyzed by Liliane Diener at Empa St. Gallen. 
MB: maternal blood space; FC: fetal capillary; ST: syncytiotrophoblast; MV: microvilli of the brush border 
membrane of the syncytiotrophoblast  
 
 
Figure 5: Macroscopic images of the human placenta after delivery. The picture shows the (A) fetal side with the 
chorionic plate and the umbilical cord and (B) the maternal side with several cotyledons.  
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Interspecies differences in placental structure 
The structure of the placenta differs massively between mammals. 
Three major types of placentas can be distinguished: the 
hemochorial (e.g. in humans, rodents, primates), the 
endotheliochorial (e.g. in dogs, cats) and the epitheliochorial (e.g. in 
pigs, horses, sheep) type. They mainly differ in the organization of 
the maternal side. As mentioned above, in the hemochorial placenta 
the fetal trophoblast is directly exposed to the maternal blood, 
whereas in the endotheliochorial placenta the trophoblast and the 
maternal blood are separated by an additional layer of maternal 
endothelial cells or in case of the epitheliochorial placenta by a 
layer of uterine epithelial cells (Enders and Blankenship, 1999).  
Each placental type can even be further divided in several subclasses. A hemochorial placenta 
can have a single trophoblast layer at term such as the human placenta (hemomonochorial), or 
up to three trophoblast layers such as the mouse placenta (hemotrichorial) (Figure 6). 
Furthermore, the placenta can be organized in different zones with distinct functions. For 
example the mouse placenta consists of a junctional zone associated with the endocrine 
function and a labyrinthine zone for the feto-maternal exchange (Dilworth and Sibley, 2013). 
In humans the syncytiotrophoblast layer throughout the whole placenta conducts both placental 
functions. In addition, the human placenta has a unique multivillous blood perfusion system 
with a pulsatile flow, while the labyrinth of the mouse placenta embraces a normal capillary 
bed (Benirschke, 2012). All these anatomical differences can lead to differences between 
different species concerning placental functions e.g. transport of xenobiotics (Dilworth and 
Sibley, 2013, Syme et al., 2004).  
 
Functions 
The placenta has various important functions to assure the proper development of the fetus. It 
regulates the exchange of nutrients, gases and waste products between mother and fetus, 
mediates maternal tolerance to fetal tissues and secretes hormones to maintain the pregnancy.  
 
Endocrine functions: The syncytiotrophoblast produces a broad variety of hormones such as 
peptide and steroid hormones. Human chorionic gonadotropin (hCG) is the earliest secreted 
product of the fetal trophoblastic tissue. It guarantees continuation of pregnancy, promotes 
Figure 6: Hemotrichorial 
structure of the mouse 
placenta with three 
trophoblast layers. 
2. Introduction 
17 
 
normal placental development, is involved in implantation and regulates trophoblast 
differentiation in an autocrine as well as paracrine manner (Verma and Verma, 2013). Human 
chorionic gonadotropin is widely used as marker for the endocrine function of healthy 
trophoblasts in several in vitro and in vivo placenta models (Malek et al., 2001, Prouillac and 
Lecoeur, 2010). Human placental lactogen (hPL) belongs also to the peptide hormones 
produced by the syncytiotrophoblast and controls the lipid and carbohydrate metabolism of the 
mother throughout pregnancy to ensure an optimal nutrient supply for the fetus (Verma and 
Verma, 2013). Leptin is another pleiotropic peptide hormone and is produced by many 
different organs such as adipose tissue, skeletal muscle, pituitary gland cells as well as 
placental trophoblast cells. Leptin modulates predominantly satiety and energy homeostasis in 
all mentioned tissues and not only during pregnancy. In the placenta leptin acts in an autocrine 
way and prevents apoptosis of trophoblast cells by promoting cell survival and proliferation, 
especially during implantation (Pérez-Pérez et al., 2013). Of note, there are many more peptide 
hormones produced by the placenta, like corticotropin releasing hormone (CRH), insulin-like 
growth factors (IGF), vascular endothelial growth factor (VEGF) or placental growth factor 
(PGH), which are involved in maintenance of pregnancy and adequate nutrient supply. 
Trophoblast cells also secrete large amounts of steroid hormones such as estrogen and 
progesterone. Progesterone plays an important role in preventing immunological rejection due 
to it anti-inflammatory and immunosuppressive functions. In addition, it decreases the 
contractility of uterine smooth muscle cells to ensure a relaxed uterus during pregnancy 
(Verma and Verma, 2013).   
 
Transport functions: The key function of the placenta is the supply of the fetus with nutrients, 
exchange of gases and the removal of waste products from the fetal circulation. Transport 
across barriers can occur via passive or active (energy-dependent) mechanisms. Passive 
mechanisms are energy-independent, whereas active mechanisms rely on the consumption of 
energy. The highly polarized syncytiotrophoblast with its two membranes carrying distinct 
transport proteins is the key exchange surface in the human term placenta (Menezes et al., 
2011). Therefore the transport mechanisms discussed below refer mainly to the 
syncytiotrophoblast. However, most of the pathways can also occur at the continuous 
endothelial layer of the fetal vessels, which mainly acts as restrictive molecular sieve (Firth and 
Leach, 1996).   
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Small non-polar, lipophilic molecules and gases cross the placental barrier by simple diffusion. 
Simple diffusion is the passive transfer of a substance driven by a concentration gradient. In 
biological systems such as the placenta diffusion is also dependent on the permeability of the 
barrier, the exchange surface area, the blood flow, the physicochemical properties of the 
substance and its capability to bind to plasma proteins or to placental tissue (Menezes et al., 
2011, Syme et al., 2004, Malek and Bersinger, 2013). Furthermore, the placenta pH plays also 
a role during placenta transfer. Due to the more acidic pH in the fetal blood compared to the 
maternal circulation, weak bases are often more ionized in the fetal compartment, which can 
lead to a higher concentration of the free unionized substance in the maternal blood and 
consequently creates gradient towards the fetus (Syme et al., 2004). Hydrophilic substances 
with low molecular weight like glucose can be still passively transferred across the placenta via 
facilitated diffusion through specialized carrier proteins or transporters, which are highly 
expressed at the brush border and basal membrane of the syncytiotrophoblast. This mechanism 
does not require energy, but is dependent on a concentration gradient and can be saturated at 
high concentrations (Syme et al., 2004). Water can enter the placenta through aquaporins or 
water channels in the syncytiotrophoblast membrane mainly driven by a pressure gradient 
(bulk flow) (Verma and Verma, 2013).  
Most ionized substances and large lipophilic molecules (molecular weight > 500 Da) have to 
be actively transported across the placenta (Syme et al., 2004). One possible mechanism is 
vesicular transport (Malek and Bersinger, 2013). Endocytotic vesicles are transported from the 
apical brush border membrane to the basal membrane of the syncytiotrophoblast (transcytosis) 
where they fuse again with the plasma membrane and release their content on the other side of 
the barrier. Transport of maternal IgG (immunoglobulin G) antibodies occurs via transcytosis, 
which is in this particular case receptor-mediated. Binding to a receptor on the brush border 
membrane specific for IgG initiates the endocytosis (Malek and Bersinger, 2013). Another 
active transport mechanism is passage through a specific transporter, which either requires 
hydrolysis of adenosine triphosphate (ATP) or an electrochemical gradient. The brush border 
and the basal membrane express a broad repertoire of different influx and efflux transport 
proteins (Ganapathy et al., 2000, Prouillac and Lecoeur, 2010). For example amino acids, folic 
acid and nucleosides are transported via such specific transport proteins. An important group of 
transport proteins highly expressed at the placental barrier is the ATP-binding cassette (ABC) 
transporter family. P-glycoprotein is one pharmacological relevant member of this family, 
located at the brush border membrane and responsible for the efflux transport of many different 
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cationic xenobiotics including morphine derivatives, antibiotics, anti-cancer as well as 
antiretroviral drugs (Ganapathy et al., 2000). 
Some studies proposed the existence of transtrophoblastic channels with a diameter around 
20 nm as another placental transfer route. Electron micrographs of the placenta from several 
species showed a narrow branched channel system through the syncytiotrophoblast, which may 
be responsible for the regulation of fetal water balance (Kertschanska et al., 1997, 
Kertschanska et al., 2000). However, these findings are controversially discussed and reliable 
evidence is still missing (Menezes et al., 2011).     
 
Metabolic functions: The extensive metabolic activity of the placenta is strongly associated 
with the endocrine and transport functions of the placenta and should also guarantee an 
appropriate supply with nutrients. This metabolic activity involves modifications, conversions, 
storage and synthesis of lipids, proteins, amino acids, vitamins and carbohydrates as well as 
detoxification of potential harmful exogenous or endogenous substances via different 
metabolizing enzymes such as the cytochrome P450 enzymes (Mathiesen and Knudsen, 2013, 
Verma and Verma, 2013). 
 
Immunologic functions: HLA tissue antigens (HLA-A,-B,-C) or major histocompatibility 
complexes (MHC) vary extremely between individuals and present small peptides derived 
from self or foreign proteins to T lymphocytes. Since the developing embryo inherits only one 
allele from the mother, the parental HLA antigens would be recognized as non-self by the 
maternal T cells which leads to rejection of the embryo. However, the absence of HLA tissue 
antigens on the syncytiotrophoblast as sole cell layer with direct contact to immune cells in the 
maternal blood, prevents fetal rejection by the maternal immune system (Verma and Verma, 
2013). Additionally, maternal immunological tolerance against the fetus is also sustained by 
placental secretion of immunosuppressive factor such as progesterone from the 
syncytiotrophoblast and cytokines (e.g. IL-10 and TGF-β) from decidua macrophages 
(Szekeres-Bartho et al., 1997, Cupurdija et al., 2004).   
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2.2.3 Models to study placental transfer 
Decades ago the placenta was considered as an impenetrable barrier. However, not only the 
discovery of the thalidomide induced birth defects in the 1960’s, but also the growing 
perception that environmental pollutants and many drugs are able to cross the placenta, led to a 
huge change in this mind-set (Martin and Holloway, 2014). Today, developmental toxicology 
of xenobiotics is an active field of research. Numerous studies show that the number of women 
who need medication during pregnancy is continuously increasing (Andrade et al., 2004, 
Gendron et al., 2009, Mitchell et al., 2011). Hence, a careful assessment of placental 
translocation of these drugs is necessary. Obviously, placental functions cannot be studied 
directly in pregnant women due to ethical concerns. Therefore, many placental models have 
been developed and used to study placental transfer and metabolism as well as embryo 
implantation. Cells and tissue isolated from the human placenta can be only obtained after 
informed consent of the pregnant woman and with approval of the local ethics committee.  
 
Placental membrane vesicles 
Membrane vesicles can be isolated from the human term syncytiotrophoblast and prepared 
from the brush border or basal membrane in order to study the expression and activity of 
specific transport proteins on each membrane separately (Boyd, 1991). Certainly, this model is 
least reflecting the in vivo situation, because of the lacking regulatory factors (Prouillac and 
Lecoeur, 2010).  
 
Placental tissue explants 
Villous explants are obtained from the human placenta, can be cultured in vitro and include 
trophoblastic, stromal, endothelial, blood as well as immune cells. They are used to study 
uptake of different substances, metabolism, endocrine functions, cell proliferation and 
differentiation. Although real kinetic transfer studies from the maternal to the fetal circulation 
are not feasible and blood flow is missing in this model, it offers the great possibility to 
investigate also pathological placental tissue and placental tissue from early gestation from 
terminated pregnancies (Miller et al., 2005). 
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Placental cell models  
Many immortal cell lines with placental origin are available to model the placental barrier. The 
most frequently used cell type is the BeWo cell line derived from a human malignant 
gestational choriocarcinoma. BeWo cells resemble undifferentiated cytotrophoblasts and are 
used to examine placental metabolism, trophoblast differentiation and syncytium formation 
(Prouillac and Lecoeur, 2010, Wice et al., 1990). Moreover, BeWo cells are cultured on a 
permeable membrane insert in a transwell system (Figure 7). This model is widely used to 
study the transport of various endogenous and exogenous substances (Li et al., 2013, 
Mathiesen et al., 2014, Bode et al., 2006). Additionally, there are also the less frequently used 
JEG-3 and JAR cell lines, which are derived from BeWo cells. However, it is controversially 
discussed if JEG-3 and JAR cells are also able to form a polarized monolayer such as BeWo 
cells, which is required for transplacental transfer studies (Bode et al., 2006). In general, the 
transwell model is suitable for long-term exposure studies and cell lines are easy to handle, but 
the model still lacks flow and tissue integrity including the endothelial cells which also 
contribute to the placental barrier. An alternative for BeWo cells is the isolation of primary 
cytotrophoblasts from the human placenta (Petroff et al., 2006). These cells form 
spontaneously a syncytium in vitro, but they do not build a tight confluent monolayer and are 
not viable for many passages (Liu et al., 1997, Yui et al., 1994). The advantages and 
disadvantages of BeWo and human primary trophoblast cells are discussed in more detail in 
chapter 3, part IV.  
 
 
Figure 7: Transwell model with BeWo cells to investigate placental transfer of xenobiotics. BeWo cells were 
cultured on a porous membrane. The xenobiotic of interest is added to the apical chamber and the transport into 
the basal chamber can be monitored over time. Adapted with permission from (Wick et al., 2014). 
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Ex vivo human placental perfusion 
The ex vivo human placental perfusion model is the ‘gold standard’ for transplacental transfer 
studies providing reliable data with a high predictability for the in vivo transfer (Grafmuller et 
al., 2013, Hutson et al., 2011). Human placentas are obtained immediately after delivery and 
are reperfused ex vivo. This method was extensively used and further optimized during my 
PhD project. The detailed perfusion procedure as well as the benefits and limitations of this 
model are described thoroughly in chapter 3, part I.  
 
Fetal/maternal blood concentration ratio 
The transfer of substances, which are administered during pregnancy anyway to treat severe 
diseases of the mother such as epilepsy, is often evaluated by analyzing the concentration in the 
maternal blood and the umbilical cord blood representing the fetal circulation. The ratio of both 
concentrations illustrates transport rate of the drug. Though, in this method the influence of 
placental drug metabolism and drug distribution in the fetal tissue are not considered (Prouillac 
and Lecoeur, 2010).     
 
Animal models 
Many placental transfer studies have been performed in mice and rats (Campagnolo et al., 
2013, Challier et al., 1973, Yamashita et al., 2011). Rodent models are perfectly suitable to 
investigate biodistribution and developmental toxicity of a specific xenobiotic. Nevertheless, 
the translation of data concerning placental transfer of xenobiotics obtained in a rodent model 
to humans is difficult or even impossible due to the huge differences in placental structure, 
physiology and implantation between the mammalian species (see section 2.2.2). Of course, 
the usage of nonhuman primates like chimpanzees with a similar placental structure (compared 
to humans) for placental transfer studies would lead to more predictable and transferrable 
results, but intensive costs, complex handling as well as ethical concerns will constrain the 
application of such models. 
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2.2.4 Current knowledge about nanoparticle-placenta interactions 
We are exposed to engineered nanomaterials (ENM) in our daily life. Their increasing 
application in several products also raised major concerns about reproductive toxicology of 
these ENMs. Recently, Buerki-Thurnherr et al. reviewed current studies on nanoparticle-
placenta interactions (Buerki-Thurnherr et al., 2012). Several epidemiological studies 
demonstrated that exposure to particulate matter (PM10 includes particles with an aerodynamic 
diameter < 10 μm and PM2.5 comprises particles with an aerodynamic diameter < 2.5 μm) in 
ambient air during pregnancy is linked with lower birth weight, preterm birth and a higher 
incidence of respiratory diseases (Bobak, 2000, Lacasana et al., 2005, Huynh et al., 2006, 
Latzin et al., 2009, Shah et al., 2011). However, none of these studies provides evidence if 
these birth outcomes were caused direct by adverse effects of the particles transported across 
the placenta or indirect by induction of inflammation in the mother and transmission of 
mediators to the placenta and the fetus. To clarify the ability of nanoparticles to overcome the 
placental barrier and induce acute toxicity in the placenta and the fetus, many different studies 
were performed using rodent and in vitro cell culture models as well as the ex vivo perfusion 
model.  
Exposure to combustion derived diesel exhaust particles in pregnant mice lead to inflammatory 
responses and DNA damage in the litter (Fujimoto et al., 2005, Reliene et al., 2005, Auten et 
al., 2012). First proof that low amounts 1.4 nm and 18 nm gold particles cross the placental 
barrier in a size-dependent manner have been shown in rats after intratracheal instillation and 
intravenous injection (Semmler-Behnke et al., 2008), while previous studies with gold colloid 
and particle exposure during pregnancy in mice did not illustrate any significant placental 
transfer (Challier et al., 1973, Sadauskas et al., 2007). Later investigations on gold 
nanoparticles also demonstrated uptake of gold particles in the murine placenta as well as 
transplacental transfer, but no toxic effects on the offspring were found (Rattanapinyopituk et 
al., 2014, Tian et al., 2013, Yang et al., 2012).  
In contrast, other ENMs such as titanium dioxide nanoparticles, amine-modified polystyrene 
beads, quantum dots, cadmium oxide nanoparticles, fullerenes, silver nanoparticles, silica 
particles and different carbon nanotubes have been reported to negatively influence the fetus in 
mice or rats (Blum et al., 2012, Campagnolo et al., 2013, Chu et al., 2010, Hougaard et al., 
2010, Huang et al., 2014, Melnik et al., 2013, Onoda et al., 2014, Pietroiusti et al., 2011, Qi et 
al., 2014, Refuerzo et al., 2011, Shimizu et al., 2009, Stapleton et al., 2013, Sumner et al., 
2010, Takeda et al., 2009, Tian et al., 2009, Yamashita et al., 2011, Yoshida et al., 2010). 
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Adverse effects such as low birth weight, higher abortion rate and impaired fetal growth, 
reproductive functions and neurobehavioral alterations of the litter were observed. The findings 
concerning placental transfer of these ENMs were quite controversial probably because of the 
different routes of particle administration, the model animal, particle coating and size.   
Transfer of polystyrene, PLGA (poly D,L-lactide-co-glycolide), iron oxide and silica particles 
also occurs in vitro in the BeWo transwell model (Ali et al., 2013, Cartwright et al., 2012, 
Correia Carreira et al., 2013, Sonnegaard Poulsen et al., 2013). Iron oxide nanoparticles even 
induce cytotoxicity in BeWo cells (Correia Carreira et al., 2013, Faust et al., 2014). Of note, 
cobalt-chromium nanoparticles indirectly cause DNA damage in fibroblast across a BeWo cell 
barrier in vitro by stimulation of cytokine production. Interestingly, the effect is more 
prominent with increasing thickness of the BeWo cell layer (Bhabra et al., 2009, Sood et al., 
2011).  
In contrast to the results of the animal experiments, gold particles show no significant transfer 
in the ex vivo human placental perfusion model, while low transfer is observed for silica 
particles, polystyrene beads and dendrimers (Menjoge et al., 2011, Myllynen et al., 2008, 
Sonnegaard Poulsen et al., 2013, Wick et al., 2010). 
Although many research studies about placental transfer of ENMs exist, only few investigated 
the determinants of transfer in a relevant experimental set-up allowing data translation to the 
human system. For example polystyrene beads are transported dependent on their size across a 
BeWo cell layer and across the placental barrier during ex vivo perfusion with a higher transfer 
of smaller beads (Cartwright et al., 2012, Wick et al., 2010). However, systematic approaches 
investigating a broader variety of particles physicochemical properties (e.g. surface charge or 
particle chemistry) responsible for placental transfer are still missing. 
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2.3 Aim of the thesis 
 
It becomes increasingly evident that a better understanding of nanoparticle-placenta 
interactions is urgently required. Since many women take medication during pregnancy, this is 
particularly important for reproductive toxicology to ensure the safety of existing ENMs and to 
prevent another case of deleterious impacts on fetal development as it happened with 
thalidomide (Martin and Holloway, 2014, Mitchell et al., 2011). Furthermore, nanotechnology 
also offers the opportunity to develop new target-orientated treatments using ENMs as drug 
carriers to either specifically treat fetal disorders (e.g. intrauterine growth restriction), placental 
complications (e.g. preeclampsia) or maternal diseases (e.g. diabetes, epilepsy). To specifically 
design nanoparticles for these purposes a greater knowledge about the physicochemical 
properties of nanoparticles, which determine the placental transfer in humans, and a better 
understanding of placental transport mechanisms of ENMs are indispensable. Only few studies 
dealt with these questions and most of them were performed in animal models, which should 
be interpreted with caution due to the huge interspecies differences in placental anatomy (see 
section 2.2.2 and 2.2.4).  
The aim of this study was to determine the influence of particle properties such as chemistry 
and surface modifications on placental transfer as well as the main transport mechanisms 
responsible for placental nanoparticle transfer in humans. As a model for investigation, the ex 
vivo human placental perfusion model was chosen based on its reliable prediction of the in vivo 
placental transfer (Hutson et al., 2011). However, since the ex vivo human placental perfusion 
model also has its limitations and is not applicable to screen a broad variety of ENMs with 
different properties, physiologically relevant advanced placental in vitro models have to be 
developed. Most placental in vitro models include BeWo cells, however it is not known yet if 
these tumor-derived cells are appropriate to reflect the placental barrier. Therefore, acute and 
subacute toxic effects of ENMs on primary human cytotrophoblast cells and BeWo cells have 
to be assessed in order to reveal if BeWo cells show similar responses as primary cells, which 
are considered as the physiological more relevant cell type.  
The combination of both models, the ex vivo human placental perfusion and the in vitro cell 
culture system should help us to better understand the transport mechanisms of ENMs across 
the placental barrier. Thus, evaluation, improvement and application of these models to 
specifically investigate interactions at the nano-placenta interface have been integral parts of 
this thesis.       
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Abstract
Decades ago the human placenta was thought to be an impenetrable barrier between mother and unborn child. However, the discovery of
thalidomide-induced birth defects and many later studies afterwards proved the opposite. Today several harmful xenobiotics like nicotine, heroin,
methadone or drugs as well as environmental pollutants were described to overcome this barrier. With the growing use of nanotechnology,
the placenta is likely to come into contact with novel nanoparticles either accidentally through exposure or intentionally in the case of potential
nanomedical applications. Data from animal experiments cannot be extrapolated to humans because the placenta is the most species-specific
mammalian organ 1. Therefore, the ex vivo dual recirculating human placental perfusion, developed by Panigel et al. in 1967 2 and continuously
modified by Schneider et al. in 1972 3, can serve as an excellent model to study the transfer of xenobiotics or particles.
Here, we focus on the ex vivo dual recirculating human placental perfusion protocol and its further development to acquire reproducible results.
The placentae were obtained after informed consent of the mothers from uncomplicated term pregnancies undergoing caesarean delivery. The
fetal and maternal vessels of an intact cotyledon were cannulated and perfused at least for five hours. As a model particle fluorescently labelled
polystyrene particles with sizes of 80 and 500 nm in diameter were added to the maternal circuit. The 80 nm particles were able to cross the
placental barrier and provide a perfect example for a substance which is transferred across the placenta to the fetus while the 500 nm particles
were retained in the placental tissue or maternal circuit. The ex vivo human placental perfusion model is one of few models providing reliable
information about the transport behavior of xenobiotics at an important tissue barrier which delivers predictive and clinical relevant data.
Video Link
The video component of this article can be found at http://www.jove.com/video/50401/
Introduction
The placenta is a complex organ which is responsible for the exchange of oxygen, carbon dioxide, nutrients and waste products and at the same
time able to keep the two blood circuits of the mother and the growing fetus separated from each other. Additionally, it prevents rejection of the
child by the maternal immune system and secretes hormones to maintain pregnancy. The cellular barrier is formed by the cytotrophoblast cells
which fuse and form a true syncytium without lateral cell membranes 4,5. The whole placenta is organized in several cotyledons, which contain
one fetal villous tree and represent one functional unit of the placenta.
The study of the placental barrier function was intensified with the discovery of the thalidomide induced malformations in the 1960's. For obvious
reasons translocation studies with pregnant women cannot be performed. Consequently, various alternative models have been developed 6,7.
The most promising and probably most clinical relevant model is the ex vivo human placental perfusion model developed by Panigel and co-
workers 2,3.
Many women are exposed to different xenobiotics such as drugs or environmental pollutants during their pregnancy 8. For some drugs which
were already administered regularly during pregnancy, in vivo studies can be performed by comparison of the maternal blood concentration with
that in umbilical cord blood. However, generally there is only limited information about the pharmacokinetics and -dynamics in the fetus and the
teratogenicity of these substances.
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For example opiates like heroin easily cross the placental barrier and can lead to intrauterine growth restriction, preterm delivery or spontaneous
abortion 9,10. So, in case of missing abstinence during pregnancy a replacement therapy with methadone is recommended. The ex vivo human
placental perfusion model revealed that the transfer of methadone into the fetal circulation is negligible 11, which correlates well with the
calculated cord blood-to-maternal blood concentration ratio after delivery 12.
Nanotechnology is a growing field especially in medicine. So, beneath the naturally occurring fine (< 2.5 μm in diameter) and ultrafine particles (<
0.1 μm in diameter) in fumes of forest fires, volcano eruptions and in desert dust, exposure to engineered nanomaterials (at least one dimension
< 0.1 μm 13) is increasing. This raised questions about the toxicological potential of engineered nanomaterials. Although no human hazard could
be proved yet, there are principal experimental studies indicating that engineered nanoparticles can cause adverse biological responses leading
to toxicological outcomes 14. Recently, some studies indicated that prenatal exposure to air pollution is linked to a higher respiratory need and
airway inflammation in newborns and children 15,16. In addition, small nanoparticles might be used as drug carriers to specifically treat either the
fetus or the mother. Therefore, it becomes evident that extensive studies of distinct xenobiotics or nanomaterials and their ability to cross the
placental barrier are required. An actual overview on the current studies on placental permeability to engineered nanomaterials is summarized in
Menezes et al. 2011 17 and Buerki-Thurnherr et al. 2012 7.
The ex vivo dual recirculating human placental perfusion model provides a controlled and reliable system for studying the placental transport of
various endogenous and exogenous compounds 3,11,12,18,19 and a wide range of other functions of the placenta like mechanisms responsible for
the development of pathological states like preeclampsia 20-22. In this protocol we focus mainly on the set up, handling and method that allow the
study of accumulation, effects and translocation rates of a broad set of xenobiotics or nanoparticles.
Protocol
1. Preparing the Perfusion System
1. Set up the perfusion system consisting of a water bath, a perfusion chamber, two columns for oxygenation, two peristaltic pumps, two bubble
traps, two flow heaters and one pressure sensor (Figure 1). Connect these components with tubing sections composed of silicone and
polyvinyl chloride materials according to the scheme in Figure 2. Finally there are two circuits representing the fetal and maternal circuit,
respectively.
2. Turn on the water bath, the flow heaters and the heating for the perfusion chamber. The temperature should be 37 °C.
3. Warm up the perfusion medium (NCTC-135 tissue culture medium diluted 1:2 with Earle's buffer (6.8 g/L sodium chloride, 0.4 g/L potassium
chloride, 0.14 g/L monosodium phosphate, 0.2 g/L magnesium sulfate, 0.2 g/L calcium chloride, 2 g/L glucose) supplemented with glucose (1
g/L), dextran 40 (10 g/L), bovine serum albumin (10 g/L), sodium heparin (2,500 IU/L), amoxicilline (250 mg/L) and sodium bicarbonate (2.2
g/L); pH 7.4) in the water bath.
4. Consecutively rinse the arterial systems of the fetal and maternal circuit with a) 200 ml distilled water, b) 50 ml 1% sodium hydroxide, c) 1%
phosphoric acid and d) again 200 ml distilled water (flow rate: 15 - 20 ml/min).
5. Connect the fetal cannula (Ø 1.2 mm; blunt needle should be attached to a modified winged needle infusion set) to the fetal arterial tubing.
6. Rinse the arterial systems of the fetal and maternal circuit with perfusion medium until all tubes contain medium (flow rate: 15-20 ml/min).
During this step fill up the bubble traps and remove all bubbles downstream of the trap. Then stop the pumps. It is really important that the
afferent arterial tubes are always free of bubbles; otherwise after cannulation especially the fine fetal vessels can rupture.
7. Turn on the gas flow. The maternal circuit is oxygenated with 5% carbon dioxide and 95% synthetic air and the fetal circuit with 5% carbon
dioxide and 95% nitrogen.
8. Start the recording of the pressure sensor.
2. Cannulating the Placenta
1. Obtain intact placentae from uncomplicated term pregnancies after primary cesarean section. Written consent has to be given (was obtained
in the case of our studies) by the mothers before delivery and the study has to be approved by the local ethics committee (was the case in
our studies). First visual control should be done by midwives to assure a healthy and intact placenta.
2. Cannulation of the placenta is a critical step! During perfusion every small disruption in the tissue can lead to a leak between the maternal
and fetal circulation. The placenta has to be obtained within 30 min after delivery.
3. Select an intact cotyledon at the marginal zone of the placenta without visible disruptions on the maternal side. At the chorionic plate, tie up
both associated branches of the umbilical artery and vein upstream to the later cannulation side (towards the umbilical cord) by using surgical
suture material. Make always two knots.
4. Cannulate the fetal artery first. The fetal placental arteries are always smaller and thinner than the veins.
5. Make a suture around the fetal artery, but do not tie it up immediately. Hold the vessel with a forceps, cut the vessel carefully and put the
small cannula (Ø 1.2 mm) in the artery. Then tie up the suture (two knots).
6. Proceed with the fetal vein in the same manner but use a bigger cannula (Ø 1.5-1.8 mm; blunt needle should be attached to a modified
winged needle infusion set).
7. Turn on the fetal pump (2 ml/min). If there is no visible leak and blood emanates out of the fetal vein cannula, slowly increase the flow up to 4
ml/min. Observe the pressure in the fetal artery, it should not exceed 70 mmHg. If fluid leaks out at the fetal or maternal cannula fix them with
another suture.
8. Place the placenta on the tissue holder with the fetal side up and pull the placental membrane and tissue over the spikes. In the end the
perfused cotyledon should be in the middle of the hole in the tissue holder.
9. Stabilize the part where only the membrane holds the placenta with a silicone membrane (Ø 1 mm) or alternatively two parafilm pieces.
10. Assemble the complete tissue holder, tighten the screws and cut the overhanging tissue. Please note that the venous and arterial cannulae
are not pinched but instead lay in the small channels of the tissue holder.
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11. Turn the tissue holder upside down, put it into the perfusion chamber and add the cover. Now, the maternal side should be at the top. Check
always if the fetal circuit is still intact and the medium is flowing out of the fetal vein tubing.
12. Turn on the maternal pump (12 ml/min). Introduce the three blunt cannulae (Ø 0.8 mm) at the end of the maternal artery tube into the
intervillous space by penetrating the decidual plate. To return the perfusate to the maternal circuit put one tube as venous drain which is also
connected with the maternal pump to the lowest position in the upper part of the perfusion chamber.
13. Connect the fetal vein cannula to the fetal vein tube.
3. Executing the Pre- and Experimental Phase of Perfusion
1. To allow the tissue to recover from the ischemic period after delivery and to flush out the blood in the intervillous space, an open pre-phase of
20 min is necessary. That means the maternal and fetal vein are not leading back to the arterial reservoir containing the perfusion medium.
Collect the fetal and maternal venous outflow in a bottle and discard it after the pre-phase.
2. To assess the integrity of the perfusion perform another pre-phase of 20 min but in a closed circuit. Use two separate reservoirs with
perfusion medium for the fetal and maternal circuit and close the circuits by leading the fetal venous outflow back in the fetal reservoir and the
maternal venous outflow back in the maternal reservoir.
3. For the main perfusion experiment prepare two flasks with 120 ml perfusion medium (one for the maternal and one for the fetal reservoir).
Add the radiolabeled 14C-antipyrine (4 nCi/ml; serves as positive control; CAUTION: radioactive substance) and the fluorescently labeled
xenobiotic or nanoparticles which one wants to analyze to the maternal reservoir. Mix the maternal perfusate well.
4. Start the experiment by exchanging the pure perfusion medium with the two prepared flasks (fetal and maternal reservoirs). Close the circuits
by leading the fetal venous outflow back in the fetal reservoir and the maternal venous outflow back in the maternal reservoir.
5. Continue the perfusion for 6 hr and take samples regularly. Always resuspend the medium in the fetal and maternal reservoir before
withdrawal.
6. Control the pressure in the fetal artery (should not exceed 70 mmHg), pH in both circuits (should be in a physiological range 7.2-7.4) and
the volume of both reservoirs (fetal volume loss should not exceed 4 ml/hr) during perfusion. If necessary adjust the pH values using either
hydrochloric acid or sodium hydroxide.
7. If the volume loss in the fetal reservoir exceeds 4 ml/hr there is a leak in the tissue and one has to stop the perfusion. The success rate of a
perfusion for 6 hr without leak is about 15-20%.
8. Stop the perfusion after 6 hr. Turn out the pumps, water bath, flow heaters and gas flow.
9. Remove the placenta from the tissue holder, cut the perfused cotyledon (brighter than the unperfused tissue) and weigh it.
10. Take samples from unperfused (part of the placenta which was cut in the beginning; could be already taken during the pre-phase) and
perfused tissue (each about 1 g) and store them at -20 °C until homogenization or in liquid nitrogen for later analysis. Fix another tissue
sample in 4% formalin for histopathological evaluation. The samples should include all layers of the placenta.
11. Clean the tubes after perfusion by successively rinsing the arterial systems of the fetal and maternal circuit with a) 200 ml distilled water, b)
50 ml 1% sodium hydroxide, c) 50 ml 1% phosphoric acid and d) again 200 ml distilled water (flow: 15-20 ml/min).
The entire working procedure of the placenta perfusion experiment is depicted in Figure 3.
4. Analyzing the Samples
1. Centrifuge the perfusate samples for 10 min at 800 x g before analysis to remove residual erythrocytes. Take the supernatant for the further
analysis. The samples can be left overnight at 4 °C. For the analysis of leptin and hCG production the samples can be stored at -20 °C.
2. To evaluate the permeability of the placenta analyze the 14C-antipyrine by liquid scintillation. Mix 300 μl of the fetal and maternal samples with
3 ml scintillation cocktail and measure for 5 min in a beta counter.
3. To assess the transfer of the fluorescent nanoparticles or the xenobiotic of interest read the fluorescence at 485 nm excitation and 528 nm
emission in a microplate reader (indicated wavelengths are for analysis of the yellow green label which we used for the nanoparticles).
4. To determine the viability of the placental tissue during perfusion measure the glucose consumption and lactate production in the fetal
and maternal circuit with an automated blood gas system. Additionally, evaluate the production of the placental hormones human
choriongonadotropin (hCG) and leptin in the homogenized tissue samples and the perfusates by enzyme-linked immunosorbent assay
(ELISA).
Representative Results
Figure 4A shows the perfusion profiles of small polystyrene particles (80 nm) which were transported across the placenta compared to bigger
polystyrene particles (500 nm) which were not transferred to the fetal compartment. Each data point represents the mean particle concentration
to the given time point of at least 3 independent experiments. For polystyrene nanoparticles the placental transfer is size-dependent 19. After
3 hr of placenta perfusion already 20-30% of the initially added 80 nm polystyrene particles were transferred from the maternal to the fetal
circuit, while the 500 nm polystyrene particles were not appearing in the fetal circuit even after 6 hr of perfusion. Nevertheless, the maternal
concentration of the 500 nm particles is decreasing. Fluorescence images on histological section of the tissue after perfusion showed that these
particles accumulate in the villi of the placenta (data not shown). Figure 4B depicts a characteristic perfusion profile of the radiolabeled 14C-
antipyrine. Antipyrine as a small lipophilic molecule is distributed over the placental barrier via passive diffusion and serves as control for the
integrity of the circuits. After 4-6 hr of perfusion an equilibrium between the fetal and maternal antipyrine concentration should be built 23. To
assess and compare the placental transport rate of xenobiotics the fetal-to-maternal drug concentration (F/M) ratio is usually displayed (Figure
5).
Through the analysis of lactate and placental hormone (human choriongonadotropin and leptin) production as well as glucose consumption the
viability and functionality of the placental tissue during the perfusion could be monitored (Figure 6). The values for the perfusions with xenobiotic
should always be in the same range as the values from control perfusion without xenobiotic. In addition, histopathological evaluation of the
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perfused placental tissue could be performed. A comparison with non-perfused placental tissue could then reveal pathological changes due to
perfusion (e.g. bacterial contamination) and therefore could serve as another quality control parameter.
Further representative results obtained with the ex vivo dual recirculating human placental perfusion model were published recently 11,19.
 
Figure 1. Ex vivo human placental perfusion set-up. 1) Water bath with maternal and fetal reservoirs, 2) perfusion chamber, 3) bubble trap, 4)
oxygenator columns, and 5) flow heater.
 
Figure 2. Schematic illustration of the ex vivo human placental perfusion model. FA: fetal artery; FV: fetal vein; MA: maternal artery; MV:
maternal vein; BT: bubble trap; PS: pressure sensor
 
Figure 3. Working procedure of an ex vivo human placental perfusion experiment. After delivery the placenta has to be cannulated within
30 min. Before the 6 hr experimental phase with recirculation an open pre-phase and closed pre-phase should be performed for at least 20 min
each.
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Figure 4. Perfusion profiles of polystyrene particles and 14C-antipyrine 19. Perfusion profile of polystyrene particles in the sizes 80 nm
(n=4) and 500 nm (n=3). Initially 25 μg/ml particles and 4.2 nCi/ml 14C-antipyrine were added to the maternal circuit. The amount of particles
(A) and 14C-antipyrine (B) were measured in the maternal (M, solid symbols) and fetal (F, open symbols) circuits after the indicated time points.
Displayed is the mean concentration ± SE. Click here to view larger figure.
 
Figure 5. Size-dependent transfer of polystyrene particles across the human placenta 19. The ratios between fetal and maternal
concentrations of 14C-antipyrine and polystyrene particles were calculated after 180 min of placenta perfusion. Data represent the mean ± SE of
at least 3 independent experiments. The control column depicts perfusions without particles but with 14C-antipyrine. (* p < 0.05 compared with 80
nm ratio value).
 
Figure 6. Viability of the placental tissue during perfusion 19. (A) Glucose consumption and lactate production in the perfused placenta.
Displayed is the sum of changes in total content in the circuits (fetal and maternal) over time divided by the weight of the perfused cotyledon.
(B) Normalized net production (NP divided by initial tissue content T0) of the placental hormones human choriongonadotropin and leptin. Data
represent the mean ± SE of at least 3 independent experiments.
Discussion
Beneath the dual recirculating perfusion showed here, there are several other experimental configurations possible depending on the question
which has to be answered. Particularly open placental perfusions are commonly used to assess the drug clearance at steady-state concentration
3. The recirculating perfusion set-up can be also applied to confirm active transport of endogenous or exogenous substances. For this approach
the same concentration of the xenobiotic has to be added to the maternal and the fetal circulation. Assumed that there is active transport against
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the concentration gradient, accumulation of the test substance in either one of the both circuits may be observed 24. Of note, the addition of the
test substance only to the fetal circuit is also feasible and can reveal the mechanism of transport across the placental barrier of this particular
substance 25.
The protocol has evolved over time and can vary between different research groups especially concerning the flow rate, composition of perfusion
medium, form of oxygenation and heating 26,27. Especially the flow rate can influence the time at which transplacental transfer occurs. To control
this, the addition of a passively transported reference compound like antipyrine is important. The transfer rate of the xenobiotic can be always
compared to the transfer rate of antipyrine (F/M ratio should be above 0.75) 26. Since the antipyrine transfer is mainly limited by the flow and
exchange surface, this comparison takes differences in the flow and the size of the perfused cotyledon into account which could vary between
the experiments. In addition, FITC-dextran could be added to the fetal circuit to serve as control for the integrity of the barrier 26. Fetal volume
loss is also used as marker for the barrier integrity. Usually a fetal fluid loss up to 4 ml/hr is allowed 28, but there is no generally accepted limit.
Obviously, there are some disadvantages of the ex vivo human placental perfusion method like inter-individual variations and a low success rate
(15-20%). Moreover, a perfusion period of 6 hr cannot simulate a chronic drug treatment and therefore can't completely exclude the transfer of
a xenobiotic after long-term exposure. Another limitation of the model is that mainly the transplacental transfer at term is assessed while the
transport rate at early gestational ages when the barrier is thicker remains still unknown. Indeed, perfusion of first trimester placentae is possible
but the availability of these placentae is rather limited. Nevertheless, up to now the ex vivo placental perfusion method is the only model to study
the transport of various xenobiotics or nanoparticles in organized human placental tissue. While toxicodynamics in the ex vivo human perfusion
model can be analyzed only in the placental tissue, animal experiments can indeed provide also information about the embryotoxicity. Though,
because of the anatomic differences of the placental barrier between humans and rodents these results cannot be extrapolated to humans 4,5.
Another possibility to investigate transplacental transfer may be cell culture models like primary cytotrophoblasts, choriocarcinoma cell lines,
isolated plasma membrane vesicles or placental tissue explants 29. The most used model is the BeWo cell line; these cells are derived from a
malignant gestational choriocarcinoma and can form a confluent monolayer on a permeable membrane, so transport studies can be performed.
Results of transport studies using the BeWo cell model correlate well with results obtained in the ex vivo human placental perfusion 30. However,
to study the details of drug transport (e.g. contribution of a specific transport protein) and metabolism, the BeWo cell model may be more feasible
primarily because it is easier to handle and susceptible to manipulation like expression of genetically altered transporters or enzymes, but
regarding general drug transfer studies the reliability of this model is limited. It lacks blood flow and the integrity of the monolayer has to be
evaluated carefully since it depends on several factors like cell culture conditions, seeding density, exposure duration and the membrane insert
6,29.
Different xenobiotics and also nanoparticles bind to various plasma proteins which can significantly influence the transplacental transfer 31;
considering the binding to plasma proteins is therefore important. The perfusion medium contains bovine serum albumin, the most frequent
plasma protein. Recently, a study showed that the transfer ratios of various substances obtained with the ex vivo human placental perfusion
model correlate well with the in vivo cord blood to maternal blood concentration ratios when the transfer ratios were adjusted according to the
extent of plasma protein binding 12.
Overall, the ex vivo placental perfusion model is a valid and reliable method to study the transport across the human placenta and to predict the
in vivo transplacental passage of xenobiotics and nanoparticles.
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Materials
Name Company Catalog Number Comments
NCTC-135 medium ICN Biomedicals, Inc. 10-911-22C could be replaced by Medium 199
from Sigma (M3769)
Sodium chloride (NaCl) Sigma-Aldrich, Fluka 71381
Potassium chloride (KCl) Hospital pharmacy also possible: Sigma (P9541)
Monosodium phosphate (NaH2PO4
· H2O)
Merck 106346
Magnesium sulfate (MgSO4 · H2O) Sigma-Aldrich, Fluka 63139
Calcium chloride (CaCl,
anhydrous)
Merck 102388
D(+) Glucose (anhydrous) Sigma-Aldrich, Fluka 49138
Sodium bicarbonate (NaHCO3) Merck 106329
Dextran from Leuconostoc spp. Sigma-Aldrich 31389
Bovine serum albumin (BSA) Applichem A1391
Amoxicilline (Clamoxyl) GlaxoSmithKline AG 2021101A
Sodium heparin B. Braun Medical AG 3511014
Sodium hydoxide (NaOH) pellets Merck 106498 CAUTION: corrosive
Ortho-phosphoric acid 85%
(H3PO4)
Merck 100573 CAUTION: corrosive
Maternal gas mixture: 95%
synthetic air, 5% CO2
PanGas AG
Fetal gas mixture: 95% N2, 5%
CO2
PanGas AG
Antipyrine (N-methyl-14C) American Radiolabeled Chemicals,
Inc.
ARC 0108-50 μCi CAUTION: radioactive material
(specific activity: 55mCi/mmol)
Scintillation cocktail (IrgaSafe Plus) Zinsser Analytic GmbH 1003100
Polystyrene particles 80 nm Polyscience, Inc. 17150
Polystyrene particles 500 nm Polyscience, Inc. 17152
EQUIPMENT
Water bath VWR 462-7001
Thermostat IKA-Werke GmbH & Co. KG 3164000
Peristaltic pumps Ismatec ISM 833
Bubble traps (glass) UNI-GLAS Laborbedarf
Flow heater UNI-GLAS Laborbedarf
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Pressure sensor + Software for
analyses
MSR Electronics GmbH 145B5
Notebook Hewlett Packard
Miniature gas exchange
oxygenator
Living Systems Instrumentation LSI-OXR
Tygon Tube (ID: 1.6 mm; OD: 4.8
mm)
Ismatec MF0028
Tubes for pumps (PharMed BPT;
ID: 1.52 mm)
Ismatec SC0744
Blunt cannulae ( 0.8 mm) Polymed Medical Center 03.592.81
Blunt cannulae ( 1.2 mm) Polymed Medical Center 03.592.90
Blunt cannulae ( 1.5 mm) Polymed Medical Center 03.592.94
Blunt cannulae ( 1.8 mm) Polymed Medical Center 03.952.82
Parafilm VWR 291-1212
Perfusion chamber with tissue
holder (plexiglass)
Internal technical department Similar equipment is available from
Hemotek Limited, UK
Surgical suture material
(PremiCron)
B. Braun Medical AG C0026005
Winged Needle Infusion Set (21G
Butterfly)
Hospira, Inc. ASN 2102
Multidirectional stopcock (Discofix
C-3)
B. Braun Medical AG 16494C
Surgical scissors B. Braun Medical AG BC304R
Dissecting scissors B. Braun Medical AG BC162R
Needle holder B. Braun Medical AG BM200R
Dissecting forceps B. Braun Medical AG BD215R
Automated blood gas system Radiometer Medical ApS ABL800 FLEX
Multi-mode microplate reader BioTek Synergy HT
Liquid scintillation analyzer GMI, Inc. Packard Tri-Carb 2200
Scintillation tubes 5.5 ml Zinsser Analytic GmbH 3020001
Tissue Homogenizer OMNI, Inc. TH-220
pH meter + electrode VWR 662-2779
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Abstract 
 
Background: Nanoparticle exposure in utero might not be a major concern yet, but could 
become more important with the increasing application of nanomaterials in consumer and 
medical products. Several epidemiologic and in vitro studies have shown that nanoparticles can 
have potential toxic effects. However, nanoparticles also offer the opportunity to develop new 
therapeutic strategies to treat specifically either the pregnant mother or the fetus. Previous 
studies mainly addressed whether nanoparticles are able to cross the placental barrier or not. 
Though, the transport mechanisms underlying nanoparticle translocation across the placenta 
are still unknown.  
Objectives: In this study we examined which transport mechanisms underlie the placental 
transfer of nanoparticles. 
Methods: We used the ex vivo human placental perfusion model to analyze the bidirectional 
transfer of plain and carboxylate modified polystyrene particles in a size range between 50 to 
300 nm.  
Results: We showed that the transport of polystyrene particles in the fetal to maternal direction 
was significantly higher than for the maternal to fetal direction. Regardless of their ability to 
cross the placental barrier and the direction of perfusion, all polystyrene particles accumulated 
in the syncytiotrophoblast of the placental tissue.  
Conclusions: Our results indicate that the syncytiotrophoblast is the key player in regulating 
nanoparticle transport across the human placenta. The mechanism underlying this translocation 
is not based on passive diffusion, but involves active, energy-dependent transport pathways. 
These findings will be important for reproductive toxicology as well as for pharmaceutical 
engineering of new drug carriers.  
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Introduction 
 
Currently the application of engineered nanoparticles (NP) in industrial and consumer products 
is increasing continuously. Epidemiological as well as in vitro studies showed that these NPs 
could have adverse health effects in humans (Oberdorster et al., 2005, Pietroiusti, 2012). 
However, to cause damage in vivo, NPs have to cross highly protective biological barriers. 
Besides the intestine and skin, the air-blood barrier of the lung is an important entry site for 
NPs. Multiple studies have shown that NPs are able to cross this protective barrier in vitro and 
in vivo (Geiser et al., 2005, Kreyling et al., 2009, Rothen-Rutishauser et al., 2007). 
Furthermore, NPs are applied in various medical products like contrast agents for imaging or 
metal oxide particles for cancer therapy (Gupta and Gupta, 2005, Rasmussen et al., 2010). 
Since these medical NPs need to be injected, they get direct access to the blood circulation. 
Therefore it will be increasingly important to investigate NP transport across internal barriers 
such as the placenta barrier between the mother and the unborn child.  
The placenta is responsible for the supply of nutrients, the removal of waste products and the 
protection of the fetus against harmful substances. It is organized in cotyledons, which 
represent the functional units of the placenta. Each cotyledon is formed by a fetal villous tree. 
Due to the extensive division of the villous trees the total exchange surface area at term is 
about 13 m2 (Larsen et al., 1995, Syme et al., 2004). The maternal blood is released into the 
intervillous space and separated from the fetal circulation by the syncytiotrophoblast layer, 
some few cytotrophoblast cells and the endothelial cell layer of the fetal capillaries, which are 
surrounded by stromal fibroblasts and fetal macrophages. The thickness of this barrier 
decreases during pregnancy to allow an increased maternal-fetal exchange at late gestational 
ages (Juch et al., 2013, Syme et al., 2004). The syncytiotrophoblast layer as key barrier is built 
from cytotrophoblast cells which fuse during development and form a true syncytium without 
lateral cell membranes (Enders and Blankenship, 1999). The plasma membrane of the 
syncytiotrophoblast is highly polarized and consists of two membranes. The basal membrane is 
in contact with the villous stroma which surrounds the fetal capillaries while the brush border 
membrane with its many microvilli faces the maternal blood stream. The polarity of the 
syncytiotrophoblast is based on a different repertoire of transport proteins for each of these 
membranes. Furthermore, there is a huge variety of transporters, which act in both directions 
(importer and exporter), to ensure an optimal supply with nutrients and an efficient efflux of 
waste products or harmful drugs (Ganapathy et al., 2000). The placental transfer of such 
substances depends on four different mechanisms: passive diffusion, active transport, 
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phagocytosis/ pinocytosis and biotransformation through metabolic enzymes (Syme et al., 
2004). 
Several animal studies showed that different NPs like gold, silica or titanium dioxide can cross 
the placental barrier and some of them can even impair fetal development (Semmler-Behnke et 
al., 2008, Yamashita et al., 2011). However, the placenta is the most species-specific organ and 
data obtained in rodent models cannot be simply extrapolated to the human system (Enders and 
Blankenship, 1999, Takata and Hirano, 1997). The ex vivo human placental perfusion provides 
an ethically accepted model, close to the in vivo situation, to investigate placental transport of 
xenobiotics as well as NPs (Grafmuller et al., 2013, Malek et al., 2009, Panigel et al., 1967, 
Schneider et al., 1972). Using this model it has been shown that 25 and 50 nm silica particles 
are transported across the human placental barrier while pegylated 10 – 30 nm gold particles 
were retained in the maternal circulation and the placental tissue (Myllynen et al., 2008, 
Sonnegaard Poulsen et al., 2013). Previous work performed by our group revealed a size-
dependent translocation of polystyrene (PS) particles with placental passage of PS particles up 
to 240 nm in diameter (Wick et al., 2010). Though there is an increasing number of in vivo and 
in vitro studies about placental NP transport (Buerki-Thurnherr et al., 2012, Saunders, 2009), 
the transport mechanisms for NPs across the placental barrier are largely unknown. Knowledge 
about the route of NP transport across the placenta barrier and about its dependency on NPs 
physicochemical properties is a prerequisite for future development of NPs as drug carriers to 
either specifically treat the mother without affecting the fetus or even to treat placental 
dysfunctions. To assess the contribution of the physicochemical properties of NPs to placental 
NP transfer and the transport mechanisms underlying this process, we performed and analyzed 
bidirectional transfer studies of fluorescently labeled PS particles with different sizes and 
surface modifications in the ex vivo human placental perfusion model.  
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Materials and Methods 
 
Particles. Yellow-green-labeled PS beads without functionalization (plain) with the size of 50 
and 240 nm from Spherotech (Lake Forest, IL, USA) were used. Yellow-green-labeled, 
carboxylate-modified (COOH) 50 and 300 nm PS beads were purchased from Polysciences 
(Warrington, PA, USA).  
Particle characterization. The zeta potential in 10 mM sodium chloride and perfusion medium 
at pH between 6.8 and 7.2 was determined with a Zetasizer NanoZS (Malvern Instruments, 
Worcestershire, UK). 
Particle size distribution in double distilled (DD) water and perfusion medium (PM) was 
determined by nanoparticle tracking analysis (NTA; NanoSight LM 20 System, NanoSight 
Ltd., Amesbury, UK) as described previously (Hole et al., 2013). The ingredients of the PM are 
described in the Supplemental Material, p. 73 - 74. The DD water and PM were filtered 
through a 0.02 µm Anotop® 25 syringe filter (Whatman GmbH, Germany) prior to analysis. 
For each particle size the results were normalized to the area under the NP concentration/size 
curve. 
The detection limit of the PS beads fluorescence was determined by making a serial dilution in 
the range of 0.02 – 10 µg/mL of each PS particle in perfusion medium. The detection limit was 
defined as the minimum concentration of PS particles in perfusion medium which showed a 
significant increase in fluorescence intensity as compared to pure perfusion medium.  
To assess the stability of fluorescence the loss of fluorescence intensity was analyzed after 
incubation of the PS beads in perfusion medium at 37 °C for 3, 6, 24, 48 and 72 hrs using a 
microplate reader (Biotek Synergy HT, Winooski, VT, USA) with excitation and emission 
wavelengths of 485 and 528 nm. The leakage of fluorescence was assessed by measuring the 
fluorescence before and after filtration through a 0.1 µm syringe filter at the end of the 
indicated incubation periods. 
Ex vivo human placental perfusion model. The placentas were obtained from uncomplicated 
term pregnancies after caesarean section at the Department of Obstetrics at the University 
Hospital Zurich, the Kantonsspital and the Klinik Stephanshorn in St. Gallen. Written informed 
consent was obtained prior to delivery. The project was approved by the local ethics committee 
and performed in accordance with the principles of the Declaration of Helsinki. The placenta 
perfusion was performed as described previously (Wick et al., 2010, Grafmuller et al., 2013). 
For a brief description see Supplemental Material, p. 73 - 74.  
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Fluorescence microscopy. Unstained paraffin sections of non-perfused (negative control) and 
perfused placenta were deparaffinized with xylene followed by 100 % ethanol. Afterwards the 
slides were air-dried, covered with VECTASHIELD® Mounting Medium containing DAPI 
(Vector Laboratories, Burlingame, CA, USA) on a glass slide and the coverslips were sealed 
with nail polish. The slides were analysed with a Leica DM6000B fluorescence microscope 
system (Leica Microsystems, Heerbrugg, Switzerland) equipped with a triple band pass filter 
set (DAPI/Spectrum Green/Spectrum Orange). All cases were photographed for documentation 
using a Leica DFC420C Camera. 
Transmission electron microscopy (TEM). Particle suspensions as supplied by the 
manufacturer were applied onto a carbon-coated copper grid and processed for TEM analysis 
(Zeiss 900 TEM, Carl Zeiss MicroImaging, Oberkochen, Germany). Samples from fetal or 
maternal circulation after 1.5 - 6 hrs of perfusion were centrifuged twice for 30 minutes at 
25000 g and 4 °C. The pellets were resuspended in DD water and processing for TEM analysis 
was performed as described for the particle suspensions.   
Statistical analysis. Data are shown as mean ± standard deviation (SD) from at least three 
independent experiments. Unpaired Student’s t-test was performed using GraphPad Prism 
software, version 6 (GraphPad Software, La Jolla, CA, USA). Differences were considered 
statistically significant at a p-value below 0.05. 
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Results 
 
Particle characterization and cytotoxicity evaluation 
The fluorescently labeled PS beads were extensively characterized and the results are 
summarized in Table 1 and Figure 1. All PS particles suspended in 10 mM sodium chloride 
solution were negatively charged, but the zeta potential of the carboxylate-modified PS beads 
was significantly lower than the one of plain PS beads in the same size range. Analysis of the 
size distribution by nanoparticle tracking analysis confirmed that the plain 50 nm and 
carboxylate-modified 50 nm PS beads were relatively monodisperse (Figure 1A, B). However, 
the plain 240 nm and carboxylate-modified 300 nm PS beads contained an additional fraction 
of smaller beads around 100 nm which were not observed to that extent in the corresponding 
TEM micrographs (Figure 1D, F). Furthermore, TEM images demonstrated that the plain and 
carboxylate-modified 50 nm PS beads contained some smaller particles of around 20 nm in 
diameter (Figure 1C, E). As expected, the hydrodynamic diameter for all PS beads in perfusion 
medium was higher than in water.  
Since a few studies showed a leakage of the fluorescence dye from NPs (Pietzonka et al., 2002, 
Tenuta et al., 2011), their stability in perfusion medium was tested over a time period of 72 hrs 
at 37 °C. After 3 hrs fluorescence intensity decreased to 75 ± 4 % of the initial signal for the 
plain 50 nm, 76 ± 2 % for the plain 240 nm, 83 ± 4 % for the carboxylate-modified 50 nm and 
84 ± 5 % for the carboxylate-modified 300 nm PS beads, but there was no further decline after 
72 hrs (see Supplemental Material, Figure S1A). This slight decrease in fluorescence intensity 
was not due to a loss of fluorescence dye from the particles, as mean leakage of the dye was 
below 0.52 % for the plain 240 nm and 2.3 % for the carboxylate-modified 300 nm PS beads 
(see Supplemental Material, Figure S1B). Filtration of the smaller beads through a 20 nm 
syringe filter was attempted, but failed due to the high viscosity of the perfusion medium and 
the obstruction of the filter. Therefore leakage of the dye could not be assessed in these 
samples. However, since the 50 nm beads were obtained from the same supplier as the larger 
particles, we assumed that they were produced with similar quality standards. 
To confirm the absence of cytotoxic effects of the PS beads an MTS viability assay was 
performed on BeWo cells. These cells were used as a model of the syncytiotrophoblast which 
will get into contact with NPs in the ex vivo perfusion system first. None of the PS particles 
decreased significantly cell viability even at higher concentrations and longer exposure time 
than those used in the ex vivo perfusion experiments (see Supplemental Material, Figure S2). 
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Table 1. Summary of PS beads characteristics 
 plain  carboxylate-modified 
 50 nm 240 nm  50 nm 300 nm 
Diameter (nm)a 49 240  42.5 302.7 
Diameter (nm)b in TEM 43.7 ± 8 220.5 ± 5.1  44.1 ± 7.1 289.4 ± 10.2 
Hydrodynamic diameter in DD water 
(nm)c 
88 ± 79.5 230 ± 65.3  68 ± 19.2 283 ± 85.2 
Hydrodynamic diameter in PM (nm)c 104 ± 74.7 273 ± 95.4  114 ± 49.1 359 ± 101.2 
Initial no. of particles/mL in PMd 5.45E+11 4.24E+09  5.30E+11 1.88E+09 
Particle surface (nm2)/mL in PMd 3.27E+15 6.48E+14  3.24E+15 4.94E+14 
Detection limit in PM (µg/mL) < 1.25 < 0.63  < 0.078 < 0.078 
Zeta potential in 10 mM NaCl (mV)b -19.8 ± 4.0 -20.5 ± 2.7  -34.7 ± 7.1 -55.6 ± 6.1 
Zeta potential in PM (mV)b -11.3 ± 6.5 -13.7 ± 5.8  -11.9 ± 11.2 -13.9 ± 7.4 
Abbreviations: DD double distilled; PM perfusion medium; TEM transmission electron microscopy 
aaccording to the manufacturer’s information; bexperimentally determined (mean ± SD); cexperimentally determined 
(mode ± SD); dcalculated values 
 
 
 
 
Figure 1: (A + B) Particle size distribution of plain (A) and carboxylate-modified (B) PS beads was measured in 
DD water (solid line) and PM (dashed line) by nanoparticle tracking analysis. (C – F) TEM micrographs of plain 
50 nm (C), plain 240 nm (D), carboxylate-modified 50 nm (E) and carboxylate-modified 300 nm (F) polystyrene 
beads in DD water.   
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Placental transfer 
In a previous study we observed a size-dependent transfer of PS beads after 3 hrs of ex vivo 
human placental perfusion in maternal to fetal direction with the highest transfer rate for plain 
50 nm PS beads (Wick et al. 2010). In the current study we investigated the bidirectional 
placental transfer of plain 50 and 240 nm as well as carboxylate-modified 50 and 300 nm PS 
particles by either adding 25 µg/mL PS beads to the maternal (M) or to the fetal (F) circulation. 
After 6 hrs of perfusion, the concentration of all PS beads was increased in reverse direction 
(F to M) as compared to normal perfusions (M to F direction) (Figure 2A, B). We observed a 
significant difference in placental transfer between normal and reverse perfusions for the plain 
50 nm (M to F 13.7 ± 8.4 % versus F to M 23.7 ± 5.8 %), the carboxylate-modified 50 nm 
(M to F 1.4 ± 0.5 % versus F to M 7.2 ± 1.3 %) and carboxylate-modified 300 nm PS beads 
(M to F 1.2 ± 0.7 % versus F to M 5.3 ± 0.5 %) (Figure 2C). Plain 240 nm PS beads also 
showed a tendency for a higher transfer in the reverse direction (M to F 2.4 ± 0.7 % versus 
F to M 6.1 ± 4.1 %) indicating a generally increased placental permeability in the F to M 
direction. In addition, we showed an increased translocation of non-functionalized 50 nm PS 
beads as compared to carboxylate-modified 50 nm PS particles in both directions indicating 
that the surface charge or modification of NPs could also influence placental NP transfer 
(Figure 2C). For the particles in the size range between 240 and 300 nm a significant difference 
between plain and carboxylate-modified beads was also observed but only in perfusions from 
M to F direction (Figure 2C). To ensure that we did not measure placental transfer of detached 
fluorescence dye, we wanted to recover the PS beads from the fetal (in case of normal 
perfusions) or the maternal (reverse perfusions) perfusates after ex vivo perfusion. In TEM 
micrographs both large (240 and 300 nm) and the plain 50 nm PS beads were found in the 
maternal perfusate after reverse perfusions, whereas in the fetal perfusate after normal 
perfusions only the plain 50 nm PS beads were detected (see Supplemental Material, Figure 
S1C). Transfer of the plain 240 nm and both carboxylate-modified beads from M to F direction 
was too low (< 0.8 µg/mL) for detection by TEM, but still within the detection limit of the 
more sensitive fluorescence measurement. Moreover, during ex vivo placental perfusion a great 
amount of other electron dense substances such as proteins or sugars were released in both 
circulations, which made it especially difficult to find the small 50 nm PS beads via TEM 
analysis. Therefore, only the plain 50 nm PS beads were detectable in TEM micrographs due to 
their high transfer in both directions.  
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Figure 2: Perfusion profiles and transfer rates of PS beads during ex vivo human placental perfusion. 
Transplacental transport of plain (A) and carboxylate-modified (B) PS beads over a time period of 6 hrs either 
from the maternal to fetal (M to F) or reverse from the fetal to maternal (F to M) circulation. Initially 25 µg/mL 
beads were added to the maternal (normal perfusions; continuous line) or fetal (reverse perfusions; dashed line) 
circulation, respectively. The amount of particles was determined by fluorescence measurement in the maternal 
(M, solid symbols) and fetal (F, open symbols) circuit at several time points. Data represents the mean particle 
concentration ± SD of at least 3 independent experiments. (C) Transfer of PS beads calculated after 6 hrs of 
perfusion. Data is expressed as mean percentage of the initially added amount of PS beads ± SD of at least 3 
independent experiments. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001  
 
As control for a passively transported substance across the placental barrier, radiolabeled 
14C-antipyrine was added to each perfusion. After 4 - 6 hrs equal concentrations should be 
reached in both circulations (Challier et al., 1983) and F to M or M to F concentration ratios 
should be around 1. This criterion was fulfilled in all perfusions demonstrating that the PS 
beads had no effect on barrier permeability itself (see Supplemental Material, Figure S3). Of 
note, the development of the concentration equilibrium of antipyrine in reverse perfusions was 
decelerated compared to perfusions in M to F direction (see Supplemental Material, Figure 
S3A). During the perfusion process there was no influence of the PS beads on viability 
(glucose consumption and lactate production) and functionality (human chorionic gonadotropin 
and leptin secretion) of the placenta (see Supplemental Material, Figure S3B, C). Moreover, no 
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visible structural changes to the placental tissue after perfusion with or without particles were 
identified in histological tissue sections (data not shown).        
Despite there was only little transfer of the plain 240 nm, carboxylate-modified 50 nm and 
300 nm PS beads in both directions, the maternal (normal perfusions) or fetal (reverse 
perfusions) concentration of these beads was declining (Figure 2A, B). Fluorescence 
microscopic images showed that these particles accumulated in the placental tissue (Figure 3). 
PS beads were mainly found in the syncytiotrophoblast layer of the placental villi independent 
of particle size, functionalization or mode of perfusion (Figure 3A, B). Unfortunately a reliable 
quantification of the PS beads in the tissue based on the fluorescence images was not possible 
because resolution is not sufficient to visualize single particles and small agglomerates which 
would lead to an underestimation of NP tissue content. Therefore we calculated the theoretical 
amount of PS beads in the tissue by subtracting the measured concentration in the fetal and 
maternal circuit from the initially added concentration (Figure 3C). After 6 hrs of perfusion the 
tissue content of the PS beads with a higher transfer rate (plain 50 nm F to M and M to F; plain 
240 nm F to M; COOH 300 nm F to M) was significantly lower as compared to the PS beads 
(COOH 50 nm M to F and F to M; plain 240 nm M to F, COOH 300 nm M to F) with only low 
placental transfer (Figure 3C).  
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Figure 3: Localization (A + B) and quantification (C) of PS beads in the placental tissue. (A) Fluorescence 
microscope images of placental tissue after 6 hrs of perfusion in normal and reverse direction with plain 50 nm, 
plain 240 nm, carboxylate-modified 50 nm and carboxylate-modified 300 nm PS beads (green). Nuclei were 
stained with DAPI (blue). (B) Fluorescence microscope images of placental tissue before and after control 
perfusions without particles. (C) Theoretical NP tissue content after 6 hrs of perfusion. Displayed is the 
percentage of initially added PS beads after subtraction of the PS fractions in fetal and maternal circuits after 6 hrs 
(mean ± SD of at least 3 independent experiments). (*) p < 0.05, (***) p < 0.001 
ST: syncytiotrophoblast; S: Stroma; FC: fetal capillary; MB: maternal blood space) 
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Discussion 
 
In this study we showed a bidirectional transfer of plain and carboxylate-modified PS beads up 
to a size of 300 nm using the ex vivo human placental perfusion model. The placental transport 
was increased in reverse perfusions from the fetal to the maternal side indicating that there are 
different transport mechanisms for PS particles on the fetal and maternal side of the human 
placenta. Although transport in the reverse direction is physiologically not relevant regarding 
in vivo exposure to NPs, which will only occur in the maternal circulation, reverse ex vivo 
placental perfusion is a common method to evaluate the mode of transport of many drugs 
across the human placenta (Nanovskaya et al., 2012, Nekhayeva et al., 2005, Sudhakaran et al., 
2005). For example a study about bidirectional placental transfer of antibiotics revealed that 
telavancin has a higher placental transfer in the reverse direction suggesting a translocation not 
simply by passive diffusion, but indicates that specific transporters may be involved 
(Nanovskaya et al., 2012). However, it is rather unlikely that NPs in general are transported via 
such transporters across the placenta (Menezes et al., 2011). Nevertheless our results 
demonstrate that passive diffusion is not the key mechanism underlying placental translocation 
of PS particles, because concentration equilibrium was not achieved after 4 – 6 hours as 
compared to the passively transported antipyrine. According to Fick’s law, diffusion of a 
substance mainly depends on the permeability of the membrane for this substance, the 
concentration gradient across the membrane and the membrane surface area. In our study 
placental transfer kinetics of antipyrine from F to M direction was significantly delayed as 
compared to M to F direction which was likely due to the lower exchange surface from the 
fetal direction (inner surface of the fetal capillaries versus the very large brush border 
membrane of the syncytiotrophoblast for the maternal direction) and the reduced fetal 
perfusion flow (3 - 4 mL/min compared to 12 mL/min for the maternal circuit) (Challier et al., 
1983). Thus, NP transfer in the reverse direction should be reduced if it would be based 
predominantly on a passive transport mechanism. However, we even observed an augmented 
transfer in F to M direction (compared to M to F) of PS particles independent of their 
physicochemical properties, suggesting an energy-dependent transport mechanism for PS 
particle translocation across the human placenta. Phagocytosis is one example of an 
energy-dependent mechanism proposed for NP uptake into cells especially in phagocytes (Jud 
et al., 2013). It has been shown that primary human macrophages engulf carboxylate-modified 
PS beads via this pathway whereas THP-1 cells, a human monocytic leukemia cell line, use an 
endocytosis pathway (Lunov et al., 2011). During phagocytosis vesicles with a diameter 
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> 0.5 µm are formed, whereas the diameter of endocytotic vesicles is considerably smaller 
(Aderem and Underhill, 1999). Caveolin coated vesicles are defined as membrane 
invaginations with a diameter of 60 to 80 nm and vesicles arising from clathrin-dependent 
endocytosis are described to have a diameter of approximately 120 to 150 nm e.g. in human 
epithelial cells (McMahon and Boucrot, 2011, Parton and Simons, 2007). A study using 
specific transport pathway inhibitors revealed that A549 cells, a human alveolar epithelial cell 
line, take up gold NPs with a diameter of 15 nm mainly by endocytosis (Brandenberger et al., 
2010). Moreover, endo- and transcytosis are also proposed as the most common transport 
mechanisms for NPs at the blood-brain barrier (Kreuter, 2014). 
Most of the studies about NP uptake mechanism were performed on non-polarized cells or cell 
lines, which do not resemble a typical polarized barrier as the placental syncytiotrophoblast. 
The different membrane properties and receptor repertoires on the apical and basal side may 
allow different transport mechanisms depending on the site of exposure. So far most groups 
observed NP uptake in the syncytiotrophblast after ex vivo human placental perfusion even if 
NP translocation to the fetal circulation was absent or below detection limit (Menjoge et al., 
2011, Myllynen et al., 2008, Sonnegaard Poulsen et al., 2013). We also observed most of the 
PS particles accumulated predominantly in the syncytiotrophoblast layer, which indicates that 
the syncytium is a major determinant of NP transfer. Besides the syncytiotrophoblast the 
endothelial cells of the fetal capillaries are also part of the placental barrier. It has been shown 
that these cells contribute to the barrier function and mostly act as a molecular sieve for larger 
hydrophilic molecules (Firth and Leach, 1996). However, to evaluate the definite contribution 
of the fetal endothelium to placental NP transfer, in vitro co-culture models including 
trophoblasts as well as endothelial cells are necessary and currently under development 
(Levkovitz et al., 2013). 
Nanoparticle uptake into cells also depends on the physicochemical properties of the materials 
(Lunov et al., 2011). We demonstrated that carboxylate-modified PS beads were transferred 
across the placenta in significantly lower amounts than plain particles. The carboxylate-
modified PS beads had a lower zeta potential than the plain beads indicating that the surface 
charge of NPs can have an impact on placental transfer. Indeed, such a surface charge-
dependent placental translocation has been demonstrated in pregnant rats where amine-
modified PS beads showed a stronger translocation than carboxylate-modified PS beads (Tian 
et al., 2009). Similar observations have been made with NPs at other biological barriers. The 
accumulation of negatively charged gold NPs in secondary organs after oral exposure in rats 
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was higher than for positively charged particles (Schleh et al., 2012). Furthermore, studies of 
NP uptake at the air-blood barrier revealed that the surface charge of NPs below a size 
threshold of 34 nm is the most critical factor for translocation (Choi et al., 2010). Differently 
charged NPs acquire a distinct protein corona after contact with serum or biological fluids 
(Hirsch et al., 2013, Lundqvist et al., 2008, Monopoli et al., 2011). The protein corona can 
influence the biological fate of NPs through alteration of their hydrodynamic diameter or 
surface properties. In addition, serum proteins can also influence directly the uptake 
mechanism of NPs by binding to their specific receptors on the cell surface, thereby mediating 
endocytosis (Monopoli et al., 2012). Several groups observed that albumin concentration in the 
perfusion medium determines the transplacental transfer of several drugs in the ex vivo human 
placental perfusion model (Mathiesen et al., 2009, Nanovskaya et al., 2008). The perfusion 
medium used in our study was supplemented with albumin only and not with complete serum. 
However, many other proteins are produced by placental cells during perfusion and are 
released into the circulation where they can get in contact with the PS beads. Interestingly, 
many hormones produced in the placenta are secreted asymmetrically into the maternal and the 
fetal circulation (Linnemann et al., 2000, Malek et al., 2001). Therefore adsorption of different 
proteins in fetal and maternal circulation may also provide an explanation for the differential 
transport in normal and reverse perfusions in our study. To corroborate this hypothesis, further 
studies with a broad variety of differently charged NPs as well as on the composition of the NP 
protein corona are required.   
Studies using the ex vivo human placental perfusion model are limited to a few hours of 
perfusion due to tissue degradation (Panigel et al., 1967, Schneider et al., 1972), and only 
reflect placental transport at late pregnancy. To assess long-term effects of NP exposure and 
transport during early stages of pregnancy, when the placental barrier is much thicker (Nikitina 
et al., 2013), in vitro studies are indispensable. In addition, in vitro studies would allow a 
higher throughput than ex vivo perfusions. So, involvement of specific transport pathways 
could be tested first in vitro and could be subsequently confirmed in the ex vivo placental 
perfusion model which is closer to the in vivo situation. Overall, development of more 
advanced and carefully validated in vitro models, which include also flow and several placental 
cell types, are expected to lead to a better understanding of NP transport mechanisms across the 
placental barrier and their dependence on the physicochemical properties of NPs.  
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Conclusions 
 
Our study is the first approach to investigate the transport mechanism of NPs by studying 
bidirectional transfer of PS particles in the ex vivo human placental perfusion model. We 
demonstrated an increased transfer of PS beads in reverse (F to M direction) perfusions and an 
accumulation of PS beads in the syncytiotrophoblast layer of the placental tissue. Based on our 
findings we can exclude a transfer via passive diffusion. We propose an energy-dependent 
placental translocation pathway and the polarized syncytiotrophoblast as the main contributor 
to NP transfer in the placenta. Though, for development and safe use of NPs in nanomedicine, 
transport mechanisms of NPs across the placental barrier need to be determined precisely in 
further studies. 
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Materials and Methods 
 
Cell culture. BeWo cells (b30 clone), a cell line derived from human choriocarcinoma, were 
obtained from Prof. Dr. Ursula Graf-Hausner (Zurich University of Applied Sciences, 
Waedenswil, Switzerland) with permission of Dr. Alan L. Schwartz (Washington University 
School of Medicine, MO, USA) and cultured in Ham´s F-12K medium (Gibco, Thermo Fisher 
Scientific Inc,, Waltham, MA, USA) supplemented with 1 % penicillin-streptomycin and 10 % 
fetal calf serum (FCS) at 37°C and 5 % carbon dioxide (CO2).  
MTS viability assay. The in vitro cytotoxicity of the different PS beads was tested using the 
MTS viability assay. 24 hrs before treatment BeWo cells were seeded in a 96-well plate (8000 
cells per well). Different concentrations of PS beads were applied. As negative control, cells 
without treatment were used and as positive control 1, 10, 100 and 1000 µM CdSO4 was 
applied. After 3 or 24 hrs of incubation at 37 °C and 5 % CO2, an MTS assay (CellTiter96® 
AQueous One Solution Cell Proliferation Assay; Promega, Madison, WI, USA) was performed 
according to the manufacturer’s instructions. Results were presented as mean percentage of the 
untreated control from three independent experiments.  
Ex vivo human placental perfusion model. A fetal artery and vein of an intact cotyledon were 
cannulated. Afterwards the placenta was fixed in a tissue holder and placed into a perfusion 
chamber. To connect the maternal side three blunt cannulas were introduced in the intervillous 
space and a venous drain was introduced to return the fluid to the maternal circuit. Two 
peristaltic pumps maintained the fetal flow at 3 - 4 mL/min and the maternal flow at 
12 mL/min. A water bath kept the temperature of both circuits at 37 °C. For the fetal side one 
oxygenator with 95 % N2 and 5 % CO2 and for the maternal side one oxygenator with 95 % 
synthetic air and 5 % CO2 were applied. To flush out the blood and allow a recovery of the 
tissue from the ischemic period after the delivery, the experiment started with an open 
perfusion (both circuits) for 20 minutes using only perfusion medium. The perfusion medium 
contained M199 tissue culture medium (Sigma, St. Louis, MO, USA) diluted with Earl’s buffer 
(dilution 1 : 2), 1 g/L glucose (Sigma, St. Louis, MO, USA), 10 g/L bovine serum albumin 
(AppliChem GmbH, Darmstadt, Germany), 10 g/L dextran 40 (Sigma, St. Louis, MO, USA), 
2500 IU/L sodium heparin (B.Braun Medical AG, Melsungen, Germany), 250 mg/L 
amoxicillin (GlaxoSmithKline AG, Brentford, UK) and 2.2 g/L sodium bicarbonate (Merck, 
Darmstadt, Germany). After closing of the fetal and maternal circulation by leading the venous 
outflow back to the corresponding reservoir, the PS particles were added either to the maternal 
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(M) or the fetal (F) reservoir at a final concentration of 25 µg/mL. The concentration of the PS 
beads in the fetal and maternal circuit was determined by fluorescence measurement in a 
microplate reader (Biotek Synergy HT, Winooski, VT, USA) after centrifugation at 800 x g to 
remove residual erythrocytes. Particle concentrations were corrected for the PM volume in the 
tubes and volume loss due to sampling before placental transfer was calculated as percentage 
of transferred PS beads compared to the initially added particle amount. As control 
radiolabeled 14C-antipyrine (50 nCi/mL, specific activity: 4.7 mCi/mmol; American 
Radiolabeled Chemicals Inc., St. Louis, MO, USA) was also added to the maternal or fetal 
circuit. The criteria for a successful perfusion were visual control (intact membranes, no lesion, 
no disruption of the placenta), leak from fetal to maternal side < 4 ml/hr (for reverse perfusions 
< 1 ml/hr), an equilibrium of 14C-antipyrine between maternal and fetal circuit after 4 - 6 hrs, a 
fetal perfusion pressure < 70 mmHg and fetal pH at a physiological range of 7.2 - 7.4.  
Antipyrine transfer. Perfusate samples were mixed with scintillation cocktail (Irgasafe Plus 
Scintillation Cocktail, Zinsser Analytic, Frankfurt, Germany) and measured in a liquid 
scintillation analyzer (Packard Tri-Carb 2200; GMI, Ramsey, MN, USA). 
Viability and functionality of the placenta. Glucose and lactate concentration in the fetal and 
maternal circuit were determined with an automated blood gas system (ABL800 FLEX 
automated benchtop analyzer, Radiometer Medical ApS, Copenhagen, Denmark). The 
placental hormones human chorionic gonadotropin (hCG) and leptin in the fetal and maternal 
circuit before and after perfusion were determined by enzyme-linked immunosorbent assay 
(ELISA) as described previously (Malek et al., 1997, Malek et al., 2001). The hormone 
production was calculated by dividing the amount released in both circulations after 6 hrs of 
perfusion by the weight of perfused tissue. 
Histopathological evaluation. Tissue samples of non-perfused (negative control) and perfused 
placentas were fixed in 4 % formaldehyde (Formafix AG, Hittnau, Switzerland). After 
standardized dehydratation of the tissue overnight in a Medite Tissue Processor TPC 15 the 
probes were embedded in paraffin blocks with the Medite Tissue Embedding System TES 99. 
Using a microtome, 4 µm thick sections were obtained, mounted and air dried on glass slides 
and stained with haematoxylin and eosin in a Tissue-Tek® Prisma™. The slides were examined 
at a Leica DMLB microscope. 
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Figure S1. Stability (A) and leakage (B) of the fluorescence dye was assessed after 3, 6, 24, 48 and 72 hrs of 
incubation at 37°C in perfusion medium. Shown are the mean percentages of initial (time point 0) fluorescence 
intensity ± SD (A) and the free fluorescence of the large PS particles as percentage of total fluorescence intensity 
± SD (B), n=3. (C) Representative TEM micrographs of plain 50 nm, 240 nm and carboxylate-modified 300 nm 
PS beads in the fetal or maternal circulation after 1.5 - 6 hrs of normal (M to F direction) or reverse (F to M 
direction) perfusion.  
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Figure S2. BeWo cell viability after 3 (A) and 24 hrs (B) of exposure to PS beads measured with a MTS assay. 
CdSO4 served as positive control for cytotoxicity. Data represent the mean percentages of viable cells compared to 
the untreated control ± SD of at least 3 independent experiments. 
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Figure S3. (A) Fetal-to-maternal (F/M) or maternal-to-fetal transfer ratio (M/F) of radiolabeled 14C-antipyrine 
over a time period of 6 hrs of normal or reverse placenta perfusion with or without PS beads. (B + C) Glucose 
consumption and lactate production (B) and human chorionic gonadotropin (hCG) and leptin hormone production 
rate (C) during ex vivo human placental perfusion with or without particles (control). All data is expressed as the 
mean ± SD of at least 3 independent experiments.  
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Abstract 
 
Nanotechnology is an expanding field not only in medicine. So, besides the naturally occurring 
fine and ultrafine particles, exposure to engineered nanoparticles is steadily increasing. This 
raises questions about the safety of such engineered nanoparticles. Thus, many researchers are 
investigating cellular responses to nanoparticles. Additionally to the toxicological know-how, 
an extensive particle characterization is fundamental to receive meaningful and comparable 
results in such studies. In this case report we present common issues, which we encountered 
during the evaluation of nanoparticles in order to determine the physicochemical properties 
responsible for placental transfer. We highlighted various challenges, for example in the 
measurement of particle size, functionalization and stability of a label such as a fluorescent 
dye. In conclusion, a careful assessment of nanoparticle properties in a physiologically relevant 
milieu is as challenging and important than the study dealing with nanoparticle-cell 
interactions itself.       
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Introduction 
 
The field of nanotechnology is growing continuously and there is intensive research 
particularly in the area of nanomedicine (Riehemann et al., 2009). To understand the 
interactions of nanoparticles (NP) with cells and their biodistribution is a pre-requisite for 
medical applications such as using NPs as carriers to deliver a drug to a specific target cell or 
organ. It has been shown that the physicochemical properties of NPs determine their fate in 
biological systems (Kreyling et al., 2010). Different NP characteristics could lead to selective 
coating with various biomolecules and therefore lead to altered cellular responses (Nel et al., 
2009). Therefore, an extensive particle characterization is indispensable. Researchers suggested 
analyzing particle size, size distribution, agglomeration state, stability, NP composition, 
endotoxin contamination, sample purity, batch-to-batch consistency, surface coating and 
reactivity (Crist et al., 2013, Warheit, 2008). There is already an increased awareness that all 
these features should be examined not only in water, but also in the physiologically relevant 
media, which are used in the respective experimental set-ups (Crist et al., 2013, Warheit, 
2008). However, in many cases properties such as dye elution, agglomeration behavior or NP 
stability in vivo cannot be predicted by in vitro testing using cell culture medium, because the 
composition of biological fluids outside and inside cells is more complex. In such situations, 
NP stability has to be assessed directly in the desired biological model.   
Here, we want to present a brief case report about the practical challenges which emerged 
during our investigations of NP transport across the human placenta. To assess transplacental 
translocation of NPs across the human placenta and to determine the physicochemical 
properties responsible for placental transfer, NPs with different characteristics are required. We 
chose polystyrene (PS) beads as model particles because they are commercially available in 
numerous sizes and with different surface modifications. The use of such commercial PS beads 
is widely established and the manufacturers already provide information about the NP 
characteristics. So, it is assumed that confirmation of such information for one random sample 
of one supplier is sufficient. Furthermore, to visualize and measure particle concentrations in a 
biologic environment such as that of the human placenta an easy detectable label is highly 
convenient. PS beads are available labeled with a range of different fluorescent dyes of high 
intensity and photostability. We evaluated plain, carboxylate- and amine-modified PS beads 
with different fluorescent labels to study placental translocation in the human ex vivo placental 
perfusion model.  
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Materials and Methods 
 
Particles. An overview of all fluorescently labeled PS beads used in this study is provided in 
Table 1. Numbers were assigned to each type of beads according to its functionalization. 
Yellow-green-labeled non-functionalized (plain) PS beads with sizes of 87 (P1) and 504 nm 
(P2), and carboxylated (COOH) PS beads with sizes of 100.8 (C1) and 533.8 nm (C2) were 
purchased from Polysciences Inc. (Warrington, PA, USA). GreenF-labeled, amine-modified 
(NH2) 100 (N1) and 250 nm (N3) PS beads were purchased from mircomod 
Partikeltechnologie GmbH (Rostock, D). Yellow-labeled, amine-modified 170 (N2) and 
530 nm (N4) PS beads were purchased from Spherotech (Lake Forest, IL, USA). Envy-green-
labeled, amine-modified 60 (N5), 250 (N6) and 510 nm (N7) PS beads were customized 
synthesized from Bangs Laboratories Inc. (Fishers, IN, USA). Orange amine-modified 110 nm 
(N8) PS beads were purchased from Sigma (St. Louis, MO, USA).  
Silica-SPIONs (superparamagnetic iron oxide nanoparticles) were kindly provided by Lionel 
Maurizi and Heinrich Hofmann (Powder Technology Laboratory, Ecole Polytechnique 
Federale de Lausanne, CH). Particle characteristics are summarized in Table 3. 
Particle characterization. The zeta potential of the PS beads in 10 mM sodium chloride and 
perfusion medium (PM) at pH between 6.8 and 7.2 was determined with a Zetasizer NanoZS 
(Malvern Instruments, Worcestershire, UK). Particle size distribution of PS beads and silica-
SPIONs in double distilled (DD) water and PM was determined by nanoparticle tracking 
analysis (NTA; NanoSight LM 20 System, software version 2.3.5, NanoSight Ltd., Amesbury, 
UK) as described previously (Hole et al., 2013). The DD water and PM were filtered through a 
0.02 µm Anotop® 25 syringe filter (Whatman GmbH, Germany) prior to analysis. For 
comparison of the different NPs the results were normalized to the area under the NP 
concentration/size curve.  
Stability of fluorescent dye. The detection limit of the fluorescence of PS beads was 
determined as described previously (Wick et al., 2010). To assess the stability of fluorescence 
the loss of fluorescence intensity was analyzed after incubation of the PS beads in PM at 37 °C 
for 3, 6, 24, 48 and 72 hours using a microplate reader (Biotek Synergy HT, Winooski, VT, 
USA) with excitation and emission wavelengths as indicated in Table 1. The leakage of 
fluorescence was assessed at the indicated time points during 72 hours at 37 °C in PM and in 
samples from the maternal circulation after 3 and 6 hours of placenta perfusion by measuring 
the fluorescence before and after filtration through a 0.1 µm syringe filter. 
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Transmission electron microscopy (TEM). Polystyrene beads and silica-SPION suspensions 
as supplied by the manufacturer were applied onto a carbon-coated copper grid and incubated 
processed for TEM analysis. Images were taken with a Zeiss EM 900 TEM (Zeiss SMT, 
Oberkochen, Germany) at 80 kV. Tissue samples (before and after perfusion) were fixed in a 
0.1 M sodium cacodylate buffer containing 3 % glutaraldehyde. After a post-fixation step in 
2 % osmium tetroxide in 0.1 M sodium cacodylate buffer, samples were dehydrated through a 
graded ethanol series followed by acetone and embedded in epon resin (Sigma, St. Louis, MO, 
USA). Ultrathin sections were contrasted with 2 % uranyl acetate and lead citrate (Reynolds, 
1963) before analysis in a Zeiss EM 900 TEM (Zeiss SMT, Oberkochen, Germany) at 80 kV. 
Ex vivo human placental perfusion model. The placentas were obtained from uncomplicated 
term pregnancies after caesarean section at the Department of Obstetrics, Zurich University 
Hospital. Written informed consent was obtained prior to delivery. The project was approved 
by the local ethics committee and performed in accordance with the principles of the 
Declaration of Helsinki. The placenta perfusion was performed as described previously 
(Grafmuller et al., 2013, Wick et al., 2010). The PM contained M199 tissue culture medium 
(Sigma, St. Louis, MO, USA) diluted with Earl’s buffer (dilution 1 : 2), 1 g/L glucose (Sigma, 
St. Louis, MO, USA), 10 g/L bovine serum albumin (AppliChem GmbH, Darmstadt, 
Germany), 10 g/L dextran 40 (Sigma, St. Louis, MO, USA), 2500 IU/L sodium heparin 
(B.Braun Medical AG, Melsungen, Germany), 250 mg/L amoxicillin (GlaxoSmithKline AG, 
Brentford, UK) and 2.2 g/L sodium bicarbonate (Merck, Darmstadt, Germany). Placental 
perfusion was started by adding 25 µg/mL PS beads or 25 µg/mL silica-SPIONs into the 
maternal circulation. The concentration of the PS beads in the fetal and maternal circuit was 
determined by fluorescence measurement in a microplate reader (Biotek Synergy HT, 
Winooski, VT, USA). Particle concentrations were corrected for the PM volume in the tubes 
and volume loss due to sampling before placental transfer was calculated as percentage of 
transferred PS beads compared to the initially added particle amount. The concentration of 
silica-SPIONs was measured after acidic digestion of the samples by analyzing iron and silicon 
concentration via inductively coupled plasma mass spectrometry (ICP-MS; Elan 6000, Perkin 
Elmer-Sciex, Waltham, MA, USA). 
Fluorescence microscopy. Tissue samples of perfused placentas were fixed in 4 % 
formaldehyde (Formafix AG, Hittnau, Switzerland), dehydrated overnight in a Medite Tissue 
Processor TPC 15 and embedded in paraffin blocks with the Medite Tissue Embedding System 
TES 99. Unstained 4 µm thick paraffin sections of perfused placenta were deparaffinized with 
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xylene followed by ethanol 100 %. Afterwards the slides were air-dried, covered with 
VECTASHIELD® Mounting Medium containing DAPI (Vector Laboratories, Burlingame, CA, 
USA) on a glass slide and the coverslips were sealed with nail polish. The slides were analysed 
with a Leica DM6000B fluorescence microscope system (Leica Microsystems, Heerbrugg, 
Switzerland) equipped with a triple band pass filter set (DAPI/Spectrum Green/Spectrum 
Orange).  
Ninhydrin assay. 20 mM ninhydrin (Fluka, Buchs, CH) solution in ethanol was added to 
1 mg/mL PS bead suspension. After 30 min at 80°C and 300 rpm absorption at 550 nm was 
measured in a microplate reader (Biotek Synergy HT, Winooski, VT, USA) (Hwang and 
Ederer, 1975).  
Statistical analysis. Data are shown as mean ± standard deviation (SD) from at least three 
independent experiments. Unpaired Student’s t-test was performed using GraphPad Prism 
software, version 6 (GraphPad Software, La Jolla, CA, USA). Differences were considered 
statistically significant at a p-value below 0.05. 
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Table 1: Summary of PS beads characteristics 
 plain carboxylate-modified amine-modified 
 P1 P2 C1 C2 N1 N2 N3 N4 N5 N6 N7 N8 
Diameter (nm)a 87 504 100.8 533.8 100 170 250 530 60 250 510 110 
Diameter (nm)b in TEM 78.1 ± 20.5 455.1 ± 32 88.8 ± 3 499.1 ± 8.3 88.4 ± 7.2 159.9 ± 5.2 224.4 ± 16.7 493.7 ± 28.7 62.5 ± 10 181.1 ± 10.7 450.7 ± 28 70.7 ± 10.8 
Hydrodynamic diameter in DD 
water (nm)c 
97 ± 0.8 445 ± 133.2 89 ± 0.7 475 ± 143.2 n.d. n.d. n.d. n.d. 78 ± 1.0 202 ± 2.1 445 ± 143.4 n.d. 
Hydrodynamic diameter in PM 
(nm)c 
132 ± 2.9 621 ± 157.1 130 ± 1.4 619 ± 186.6 n.d. n.d. n.d. n.d. 112 ± 0.9 328 ± 2.2 658 ± 9.1 n.d. 
Initial no. of particles/mL in PMd 9.55E+10 4.82E+08 6.49E+10 3.66E+08 6.58E+10 1.11E+10 4.02E+09 3.78E+08 1.86E+11 7.66E+09 4.97E+08 1.29E+11 
Particle surface (nm2)/mL in PMd 1.83E+09 3.14E+08 1.61E+09 2.86E+08 1.62E+09 8.93E+08 6.37E+08 2.89E+08 2.29E+09 7.89E+08 3.17E+08 2.02E+09 
Detection limit in PM (µg/mL) < 0.078 < 0.21 < 0.078 < 0.039 n.d. n.d. < 2.5 < 0.02 < 0.078 < 0.078 < 0.039 n.d. 
Zeta potential in 10 mM NaCl 
(mV)b 
-50 ± 9.7 -46.9 ± 4.0 -38.2 ± 10.4 -55.6 ± 4.3 n.d. n.d. n.d. n.d. -30.2 ± 8.2 -36.2 ± 4.4 -38.9 ± 2.7 n.d. 
Zeta potential in PM (mV)b -13.1 ± 7.2 -14.5 ± 6.6 -13.1 ± 10.1 -15.3 ± 8.3 n.d. n.d. n.d. n.d. -12.7 ± 5.4 -14.1 ± 9.9 -17.3 ± 5.7 n.d. 
Fluorescent dye Yellow green Yellow green Yellow green Yellow green GreenF Yellow GreenF Yellow Envy green Envy green Envy green Orange 
Dye excitation/emission (nm) 485/528 485/528 485/528 485/528 475/510 485/520 475/510 485/520 525/565 525/565 525/565 481/644 
Number of perfusions 3 3 4 4 1 0 4 3 3 3 3 1 
Abbreviations: DD double distilled; PM perfusion medium; TEM transmission electron microscopy; n.d. not determined 
aaccording to the manufacturer’s information; bexperimentally determined (mean ± SD); cexperimentally determined (mode ± SD); dcalculated values
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Results and Discussion 
 
NPs were carefully characterized and their properties are displayed in Fehler! Verweisquelle 
konnte nicht gefunden werden.. During our investigations we encountered different 
problems, which did not allow conducting a reasonable NP translocation study. A brief 
overview of the practical challenges during evaluation of different NP types is provided in 
Table 2 and the topics, size, surface modification and charge as well as dye stability will be 
discussed extensively. 
  
Table 1: Summary of the encountered problems for each PS bead type 
PS beads Size Surface modification/charge Fluorescent dye 
P1 Mixture of differently sized beads   
P2 Bimodal size distribution   
N1   Dye leakage after ex vivo placental perfusion  
N2 Mixture of differently sized beads   
N3   
Dye elution after 24 and 72 
hours at 37°C in PM; 
Dye leakage after ex vivo 
placental perfusion (> 20 % 
fluorescence from free dye) 
N4   
Dye leakage after ex vivo 
placental perfusion (> 20 % 
fluorescence from free dye) 
N5 Mixture of differently sized beads 
Negative instead of positive 
surface charge  
N6  Negative instead of positive surface charge 
Dye elution only after 24 
hours at 37°C in PM 
N7  Negative instead of positive surface charge 
Little dye leakage after ex vivo 
placental perfusion (about 11 
% fluorescence from free dye) 
N8 Mixture of differently sized beads   
Note: For C1 and C2 no problems were found regarding the tested properties. 
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Size 
To unambiguously identify the influence of NP size on placental translocation, a monodisperse 
suspension is a prerequisite. During evaluation of PS beads for our study, we experienced that 
obtaining PS beads with a narrow size distribution is quite challenging. Often particle 
suspensions are contaminated to some extent with beads of a smaller diameter than stated by 
the manufacturer (Figure 1). The TEM micrographs in Figure 1A illustrate that the PS beads 
P1, P2, N2, N5 and N8 actually contained particles with various sizes whereas the 
manufacturer declared one size determined by dynamic light scattering (DLS). DLS measures 
the average hydrodynamic diameter (d) of particles and the intensity of the scattered light is 
proportional to d6 (the diameter raised to the power of 6). This term means that a 500 nm 
particle will scatter 106 times more light than a 50 nm particle. Therefore, DLS measurement is 
usually biased towards large particles and often prevents the detection of small NPs in 
polydisperse mixtures. An alternative method for such mixtures is the nanoparticle tracking 
analysis (Nanosight). This method doesn’t determine the average particle size, but tracks the 
movement of individual particles in a fluid on a particle-by-particle basis and thus allows a 
discrimination of differently sized particles in a polydisperse suspension. However, analyzing 
particle size distribution by nanoparticle tracking analysis only detected the contamination with 
smaller beads for larger beads such as P2 (about 500 nm), while PS beads with a diameter 
around 50 nm such as N5 were already at the detection limit of this method (Figure 1B). For 
the latter a contamination with smaller beads could only be detected by another method such as 
TEM analysis. Similar observations that the manufacturer’s size information needs to be 
confirmed preferably by a complimentary technique have been made for other NPs. Some 
silver NPs showed significant differences in size between the information from the 
manufacturer and TEM analysis (Zheng et al., 2011). Besides the measuring technique also the 
conditions during the measurements have an impact on the results. For example the 
hydrodynamic diameter of gold particles determined by DLS increased after contact with 
human plasma (Dobrovolskaia et al., 2009). Consequently, to assess the diameter also in a 
physiological relevant medium is crucial for experiments carried out in a biological 
environment.    
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Figure 1: (A) TEM micrographs of PS bead suspensions in DD water with low and high magnification (upper left 
corner). (B) Size distribution of PS beads was determined by nanoparticle tracking analysis. 
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Surface modification and charge 
Specific particle shells or surface coatings are added to NPs for example to prevent aggregation 
or to provoke a specific effect in vivo. In addition, such coatings are also important parameters 
to induce toxicity or accelerate transport into cells or across barriers (Oberdorster et al., 2005). 
In order to determine the influence of NP surface modification and charge on placental 
transfer, it is crucial to confirm the presence of these functionalized groups. In ex vivo placenta 
perfusion experiments, we observed a difference in placental transport between plain, 
carboxylate-modified and amine-modified PS beads (Figure 4). Plain PS beads (P1 and P2) but 
not amine-modified N5, N6 and N7 PS beads were transported across the placental barrier 
suggesting that the surface modification is a major determinant of placental translocation 
(Figure 4D). Zeta potential measurements revealed that contrary to expectations, these amine-
modified NPs were strongly negatively charged. Since the fluorescent dye in the particles is 
slightly negatively charged, it might be that the density of the amine functionalization on the 
PS beads was not high enough to cause a positive zeta potential. Besides an insufficient 
functionalization, the particle suspensions could also contain residues of sodium dodecyl 
sulfate (SDS). SDS is used as surfactant during synthesis of PS beads and is negatively 
charged. Normally SDS is removed after NP synthesis by dialysis against water.  However, 
small residual amounts of SDS in combination with a low amine group density could explain 
the negative zeta potential. Hence, a direct detection of the chemical amine group would be 
required, but the attempt to detect the amine groups on the particle surface by the colorimetric 
ninhydrin assay failed due to NP interference with the assay. Primary amine groups react with 
ninhydrin and form a purple compound, which leads to an increased absorbance at 570 nm. 
The internal fluorescence of the PS beads caused a false positive signal and, thus, a difference 
in intensity before and after ninhydrin treatment could not be observed (Figure 2). 
Consequently, the ninhydrin assay is not suitable to confirm the presence of functional amine 
groups attached to fluorescently labeled NPs and analytical methods such as infrared 
spectroscopy may be considered for further studies. 
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Figure 2: To assess the presence of amino groups on the surface of PS beads N5, N6 and N7, a ninhydrin assay 
was performed. The amino acid glycine served as positive control. Absorption was determined at 550 nm and 
mean ± SD of 2 technical replicates is displayed.  
 
In vitro and ex vivo elution of fluorescent dyes 
Several studies demonstrate that a fluorescent dye can elute from NPs after contact with 
biological fluids (Pietzonka et al., 2002, Salvati et al., 2011, Tenuta et al., 2011, Mahon et al., 
2012). Therefore, we tested the fluorescent dye stability of the PS beads after incubation at 
37 °C for up to 72 hours in PM. The fluorescence intensity of the greenF-labeled N3 and the 
yellow-green C1 PS beads remained completely stable over 72 hours and only the N3 PS beads 
showed an elution of fluorescent dye from the particles (43.1 ± 9.3 % of total fluorescence 
intensity was from free fluorescent dye after 24 hours) (Figure 3A, B). For all other PS beads 
the fluorescence intensity decreased to 60 – 80 % of the initial signal after 72 hours (Figure 
3A). Figure 3B indicates that this loss in fluorescence intensity was not due to a significant 
leakage of fluorescent dye except for the envy green-labeled N6 PS beads, which showed a 
transient release of dye after 24 hours (25.3 ± 5.2 %). Due to technical issues, PS beads with a 
diameter of 100 nm and below could not be analyzed for fluorescence leakage. Syringe filters 
with a smaller pore size than 0.1 µm, which are required to separate the free fluorescent dye 
from the particles, were not applicable because components of the PM lead to a clogging of the 
filter. The overall reduction of the measured fluorescence intensity for most of the PS beads 
(P1, P2, C2, N4, N5, N6, N7) after incubation in PM might be caused by adsorption of albumin 
or other components of the medium to the NPs, which might impair the fluorescence signal. 
The adsorption or binding of proteins and other molecules to NPs occurs usually rapidly and is 
saturated after a certain time point (Cedervall et al., 2007, Tenzer et al., 2013). Thus, the fact 
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that the fluorescence intensities are not further declining after 3 – 6 hours would corroborate 
this hypothesis. However, whether a shell of adsorbed molecules is the cause of the 
fluorescence intensity loss in PM remains to be determined in additional studies.  
 
 
Figure 3: (A) Fluorescent dye stability of PS beads in perfusion medium at 37 °C over 72 hours. Displayed is the 
percentage of initial fluorescence intensity at several time point compared to time point at 0 hours (mean ± SD; 
n=3). (B) Leakage of the fluorescent dye of the large PS beads during 72 hours at 37 °C in perfusion medium. 
Data is expressed as percentage of free fluorescence of total fluorescence intensity (mean ± SD; n=3). (C) Elution 
of fluorescent dye of the large PS beads after 3 and 6 hours of ex vivo placental perfusion. Data is expressed as 
percentage of free fluorescence of total fluorescence intensity (mean ± SD of at least 2 independent experiments). 
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Figure 4: (A + B) Perfusion profiles after ex vivo human placental perfusion of amine-modified PS beads N1 
(n=1), N3 (n=4), N4 (n=3), N5, N6, N7 (all n=3), N8 (n=1). (C) Perfusion profiles of plain and carboxylate-
modified PS beads P1, P2, C1 and C2 of at least 3 independent experiments. Data is expressed as mean particle 
concentration (µg/mL) in the fetal (F) and maternal (M) circulation determined by fluorescence measurement at 
the indicated time points ± SD. (D) Percentage of plain and carboxylate-modified PS beads (P1, P2, C1, C2) in the 
fetal circulation after 6 hours of perfusion compared to the initially added particle amount (mean ± SD of at least 3 
independent experiments). (*) p < 0.05, (**) p < 0.01 
 
Although dye elution was not a major problem for most PS beads after incubation in PM, it 
became an important issue after contact with the human placenta. During placenta perfusion 
the greenF-labeled N1 and N3 PS beads showed an unexpected perfusion profile (Figure 4A). 
After addition of 25 µg/mL PS bead into the maternal circulation, the total concentration (fetal 
and maternal circuit) seemed to increase above the initially added amount during placental 
perfusion. Further analysis of samples from the fetal and maternal circulation after 6 hours of 
perfusion revealed that 47.9 ± 8.3 % of the fluorescent dye was leaking out of the greenF-
labeled N3 PS particles (Figure 3C). Although the perfusion profile of the yellow-labeled N4 
PS particles appeared more rational, the filtration also showed 36.4 ± 33.8 % leakage of the 
fluorescent dye after 6 hours of perfusion (Figure 3C, and 4A). According to the particle 
supplier, the fluorescence in the particles is partially quenched because of the heavy dye-
loading, thus we suggest that the perfusion profile showed an increased fluorescence in the 
maternal circuit due to the fact that the free dye generates a higher fluorescence. Consequently, 
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the increased fluorescence intensity in the fetal circulation was likely due to the rapid transfer 
of the free dye across the placental barrier. GreenF and yellow are fluorescein derivatives and it 
has been shown that such small hydrophobic chemical compounds can easily cross the placenta 
(Menezes et al., 2011). Regardless of the fluorescence leakage, analysis of histological sections 
of placental tissue after perfusion by fluorescence microscopy still showed some fluorescent 
particles in the syncytiotrophoblast and the villous mesenchyme (N3 and N4 in Figure 5 
compared to stable particles N5, N6, N7 and P1, P2, C1, C2 in Figure 6). We were not able to 
detect a difference in fluorescence distribution within the cells as described previously for 
rhodamine labeled N-isopropylacrylamide (NIPAM) NPs which were found to elute dye and 
the free dye was spread in the whole cell and particle-bound dye was only restricted to 
organelles such as lysosomes (Tenuta et al., 2011). According to the NP suppliers the water 
insoluble fluorescent dyes were incorporated in the glassy polymer matrix after swelling in an 
appropriate solvent and are not chemically bound in the particle or to the surface. Therefore all 
dyes should remain entrapped in an aqueous environment. However, as every biological 
environment the placental tissue consists of several compartments with different pH values and 
containing different proteins or lipids. It is known that dyes can elute from NPs after contact 
with a hydrophobic milieu in a cell (Pietzonka et al., 2002, Salvati et al., 2011). The plasma 
membrane of a cell retains an enormous hydrophobic area which is especially enlarged in the 
human placenta compared to other organs. The brush border membrane of the placental 
syncytiotrophoblast, which is in contact with the maternal blood, forms numerous microvilli to 
gain a huge surface for effective exchange of nutrients and waste products. Hence, the 
possibility of NP contact with hydrophobic membrane in the placenta is much higher than in 
other biological tissues and therefore the probability of dye elution is increased. Of note, the 
placenta is an organ with an increased enzymatic and metabolic activity due to its physiological 
function to protect the fetus and detoxify harmful substances (Prouillac and Lecoeur, 2010, 
Aye and Keelan, 2013). So it could also be conceivable that parts of the greenF and yellow 
amine-modified PS particles were degraded by the placental cells which lead to the release of 
the fluorescent dye. Since this phenomenon could not be observed with the non-functionalized 
and carboxylate-modified PS beads this fluorescence leakage seems to be dependent on the 
surface modification. However, examinations with amine-modified N5, N6, N7 and N8 PS 
beads containing a different fluorescent dye (envy green and orange) revealed a fraction of 
only 3.9 ± 5.2 % and 11.2 ± 9.1 % free dye after 6 hours of perfusion for N6 and N7 nm PS 
beads, respectively, indicating that dye elution depends mainly on the properties of the 
fluorescent dye (Figure 3C and 4B).  
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Figure 5: Representative fluorescence microscope images of amine-modified PS beads in placental tissue after 6 
hours of ex vivo perfusion. As control placental perfusion without addition of particles was performed. PS 
particles are displayed in green and nuclei are stained with DAPI (blue). Due to autofluorescence erythrocytes 
appear also in green. Red arrows indicate accumulated PS beads. 
 
 
Figure 6: Representative fluorescence microscope images of plain and carboxylate-modified PS beads in 
placental tissue after 6 hours of ex vivo perfusion. PS particles are displayed in green and nuclei are stained with 
DAPI (blue). Due to autofluorescence erythrocytes appear also in green. Red arrows indicate accumulated PS 
beads. 
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To avoid the problem of dye leaching, we wanted to use silica-iron core-shell nanoparticles 
(silica-SPIONs) instead of polystyrene (Table 3, Figure 7). The elements silicon and iron in 
these particles can be directly detected by ICP-MS analysis. Unfortunately, first measurements 
indicated that these elements are already present in the placental tissue and the perfusion 
system itself (Figure 8). Therefore it will be very difficult to interpret the diverse results 
obtained after ex vivo placental perfusion especially if only low placental transfer is expected 
(Figure 9A). Indeed, TEM micrographs of placental tissue after perfusion implied such a low 
transport rate, because silica-SPIONs were exclusively found in the maternal part of the 
placenta mainly in macrophages lying in the intervillous space or near the brush border 
membrane of the syncytiotrophoblast (Figure 9B). Overall, using nanoparticles without 
fluorescent label for transport studies in a biological context requires a careful evaluation of the 
background levels of the respective elements in this environment and the experimental system 
prior to analysis.  
 
 
Table 2: Summary of silica-SPIONs characteristics 
 Silica-SPIONs 
Diameter (nm)a  in TEM 46 ± 10 
Hydrodynamic diameter in DD water 
(nm)b 
125 ± 68.6 
Hydrodynamic diameter in PM (nm)b 145 ± 66.9 
Zeta potential in DD water (mV)a -33 ± 0.6 
Iron content (mgFe/mL) a 0.42 
Silica content (mgSiO2/mL)c 6.84 
Abbreviations: SPION superparamagnetic iron oxide nanoparticles 
aaccording to the manufacturer’s information; bexperimentally determined (mode ± SD);ccalculated values 
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Figure 7: (A) TEM micrographs of silica-SPIONs in DD water. (B) Size distribution of silica-SPIONs in DD 
water and perfusion medium.  
 
 
Figure 8: Background levels of silicon (Si) and iron (Fe) in the perfusion system and placental tissue. Si and Fe 
concentrations of solutions (1 % NaOH, 1 % H3PO4, DD water) used to clean the perfusion system, perfusion 
medium (PM), silica-SPION suspensions, control perfusions (without particles) as well as tissue samples were 
measured by ICP-MS. 
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Figure 9: (A) Silicon and iron concentration in the fetal (F) and maternal (M) circulation during 4 hours of 
perfusion with silica-SPIONs was determined by ICP-MS. Data is expressed as mean concentration ± SD (n=2). 
(B) TEM micrographs of placental tissue after 6 hours of perfusion with silica-SPIONs. Left and middle panels: 
Arrows indicate vesicles filled with silica-SPIONs in a macrophage. Middle panel is a magnification of the 
marked vesicle in the left panel. Right panel: Arrows indicate silica-SPIONs in the maternal blood space near the 
microvilli of the syncytiotrophoblast. 
MB maternal blood space; ST syncytiotrophoblast; M maternal macrophage 
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Conclusions 
 
Our results demonstrate that there are many practical challenges during investigations about the 
influence of physicochemical properties of NPs on transport across biological barriers like the 
human placenta. The characteristics of NPs such as size distribution, fluorescent dye leakage 
after contact with biological fluids and stability of surface modifications have to be assessed 
carefully in order to gain reasonable information and understand how NP characteristics such 
as size, surface charge and chemistry determine not only placental transport but also cellular 
responses and uptake mechanisms in general. The parameters of NPs physicochemical 
properties, which have to be analyzed in physiologically relevant conditions, should be always 
selected according to the question of the study and the biological system. Despite the 
increasing commercial availability of various NPs with distinct characteristics, the extensive 
characterization of NP properties requires a similar effort as the investigation of the 
nanoparticle-cell interactions itself. Finally, this represents a real interdisciplinary challenge.   
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Introduction 
 
Decades ago the human placenta was thought to be an impenetrable barrier between mother 
and unborn child. However, the discovery of the thalidomide-induced birth defects and many 
later studies proved the opposite. Today several harmful xenobiotics like nicotine, heroin or 
methadone as well as environmental pollutants were described to overcome this barrier (Martin 
and Holloway, 2014). With the increasing use of engineered nanomaterials (ENM) in many 
industrial, consumer and medical products, concern about nanoparticle exposure in utero is 
arising. To elucidate the risk of such ENMs to the developing fetus, placental transport studies 
are required. In addition, a high percentage of women need medication during pregnancy (such 
as epilepsy drugs) despite of known adverse effects of these drugs for the fetus (Gendron et al., 
2009). Nanomedicine is anticipated to provide novel therapeutic strategies to overcome off-
target effects to the fetus e.g. by developing nanoparticle drug carriers that are largely retained 
in the maternal circulation. A better understanding of the specific mechanisms underlying 
placental transfer of ENMs and its dependence on the physicochemical properties is a 
prerequisite for the development of ENMs as drug carriers. Since the placenta is the most 
species-specific organ in mammals, animal models are not appropriate to predict placental 
transfer in humans (Enders and Blankenship, 1999). To date the ex vivo human placental 
perfusion model is the most reliable and predictive model to study placental transport of ENMs 
and xenobiotics in general (Grafmuller et al., 2013). However, it has its limit regarding 
throughput and time of exposure. Due to a success rate of about 20 % for a 6 hour placental 
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perfusion, only some pre-selected ENMs and questions can be investigated in a reasonable 
time frame. Duration of exposure to ENMs in the ex vivo perfusion model is restricted to few 
hours because of tissue degradation (Panigel et al., 1967, Schneider et al., 1972, Di Santo et al., 
2003). Long-term effects on the placenta as well as specific transport mechanisms have to be 
studied in an in vitro model first. The most often used in vitro model for the human placenta is 
the transwell model with BeWo cells, a human cell line derived from a malignant gestational 
choriocarcinoma (Ali et al., 2013, Bhabra et al., 2009, Cartwright et al., 2012, Correia Carreira 
et al., 2013, Faust et al., 2014, Sood et al., 2011). BeWo cells resemble the cytotrophoblast 
cells, which fuse during placental development and form a syncytium. The resulting 
syncytiotrophoblast is the main cellular barrier of the human placenta (Enders and 
Blankenship, 1999). Though, the endothelial cells of the fetal capillaries may also play a role in 
regulating placental transport of endogenous and exogenous substances (Elad et al., 2014, Firth 
and Leach, 1996, Levkovitz et al., 2013b). Currently, only few models exist which include 
both cell types and most transport experiments are conducted under steady state conditions so 
far (Levkovitz et al., 2013a). Therefore, the aim of our group is to develop an advanced in vitro 
model including several cell types and perfusion flow allowing mechanistic studies and a 
higher throughput compared to the ex vivo perfusion model. Additionally, a three-dimensional 
placental tissue model with a fibroblast core and a trophoblast shell is under development using 
the hanging drop technology. At the moment BeWo cells are used in both models, because they 
are stable, easy to handle and build a confluent cell layers in culture. However, this cell line 
comprises mainly undifferentiated cytotrophoblasts, which do not spontaneously form a true 
syncytium without lateral cell membranes as the syncytiotrophoblast in vivo (Wice et al., 
1990). Thus to exclude paracellular transport, the formation of tight junctions has to be 
evaluated prior to a transport study which is usually done by measurement of the transepithelial 
electrical resistance (TEER) and transfer of marker molecules such as fluorescein (Cartwright 
et al., 2012). To optimize the model, primary cytotrophoblast cells isolated from the human 
placenta could replace the BeWo cells. We hope this will improve the in vivo predictability of 
the model not only for transport but also for placental toxicity studies. Primary human 
cytotrophoblasts syncytialize spontaneously and form a polarized syncytium. In this stage the 
cells are highly differentiated and there is no cell division anymore similar as in vivo. In 
contrast, BeWo cells are largely undifferentiated with an extensive proliferation activity, which 
is typical for cancer cells. Consequently, the cellular responses to ENMs (e.g. influence on 
functionality) could be quite different in tumor derived BeWo cells with an altered gene 
expression and primary cytotrophoblasts (Bilban et al., 2010, Nikitina et al., 2013). The aim of 
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this still ongoing study is to elucidate if BeWo cells and primary trophoblasts show a different 
behavior after exposure to ENMs based on the assumption that primary cytotrophoblasts are 
more physiological relevant and predictive as model for placental studies. In order to reach this 
goal, acute toxicity induced by ENMs, uptake as well as the impact of ENMs on the endocrine, 
metabolic and transport function of both cell types have to be compared. To evaluate a broad 
variety of cellular responses, different toxic and non-toxic ENMs such as multi-walled carbon 
nanotubes (MWCNTs), gold and polystyrene (PS) particles are used in this study. For the 
MWCNTs and amine-modified PS beads cytotoxic effects on other cell types have already 
been described (Elliott et al., 2014, Thurnherr et al., 2011).  
 
Materials and Methods 
 
Nanomaterials. Amine-modified (NH2) 58 nm PS beads were purchased from Bangs 
Laboratories Inc. and were characterized by Elliott and Rösslein et al. (Elliott et al., 2014). 
Gold nanoparticles (NPs) modified with positive, neutral and negative ligands were kindly 
supplied and characterized by Dr. Bing Yan from Shandong University, Jinan, China (Table 1). 
MWCNTs were obtained from Bayer Technologies Services and were extensively 
characterized by Thurnherr et al. (Thurnherr et al., 2009). Prior to each experiment MWCNTs 
were dispersed in 160 ppm Pluronic F127 (Sigma-Aldrich) by sonication for 10 min in an 
ultrasonic bath at a concentration of 500 µg/mL.  
 
Table 1: Summary of gold nanoparticles characteristics 
 Positive 
 
Neutral 
 
Negative 
 
Diameter (nm)  in TEMa 5.76 ± 0.99 5.79 ± 0.43 4.55 ± 0.18 
Diameter from DLS in DD 
watera 
70.68 ± 7.8 106.1 ± 1.37 147.7 ± 0.87 
PDI in DD water 0.332 0.154 0.191 
Zeta potential in DD water 
(mV) at pH 7a 
38.6 ± 0.75 -33.2 ± 2.12 -39.8 ± 1.7 
Abbreviations: TEM transmission electron microscopy; DD double distilled; PDI polydispersity index 
aMean ± SD 
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Cell culture. BeWo cells (b30 clone) were obtained from Prof. Dr. Ursula Graf-Hausner 
(Zurich University of Applied Sciences, Waedenswil, Switzerland) with permission of Dr. 
Alan L. Schwartz (Washington University School of Medicine, MO, USA) and cultured in 
Ham´s F-12K medium (Gibco, Life Technologies) supplemented with 1 % penicillin-
streptomycin-neomycin (Sigma-Aldrich) and 10 % fetal calf serum (FCS; Lonza). Cells were 
grown in tissue culture flasks at 37 °C and 5 % CO2 and sub-cultured at 80 % confluency using 
0.05 % Trypsin-EDTA (Ethylenediaminetetraacetic acid) (Sigma-Aldrich) for detachment. 
Isolation of primary human cytotrophoblasts. Human placentas were obtained from 
uncomplicated term pregnancies after caesarean section at the Department of Obstetrics at the 
Kantonsspital and the Klinik Stephanshorn in St. Gallen. Written informed consent was 
obtained prior to delivery. The project was approved by the local ethics committee and 
performed in accordance with the principles of the Declaration of Helsinki. Isolation of 
primary cytotrophoblasts was performed as described elsewhere (Petroff et al., 2006). After 
placing the placental tissue in a sterile plate (maternal side at the top) on ice, the superficial 
basal plate tissue on the maternal side was carefully removed. Above the chorionic plate lies 
the villous tissue from which 50 g were collected and rinsed with phosphate-buffered saline 
(PBS; Sigma-Aldrich) until the remaining blood was washed out. Three consecutive steps of 
tissue digestion in digestion solution containing 25 mM HEPES (4-(2-Hydroxyethyl)
piperazine-1-ethanesulfonic acid; Sigma-Aldrich), 0.25 % Trypsin (Invitrogen, Life 
Technologies) and about 300 U/mL DNase (Sigma-Aldrich) in 1x HBSS (Hank’s balanced salt 
solution consisting of 0.54 mM KCl, 0.44 mM KH2PO4, 0.14 M NaCl, 0.34 mM Na2HPO4 and 
5.55 mM D-glucose dissolved in DD water) followed. Each step was carried out for 20 min at 
37 °C. After each step the supernatant was collected and new digestion solution added. The 
supernatant was filtered through a cell dissociation sieve (60 mesh screen with a pore size of 
about 230 µm; Sigma-Aldrich) and layered over FCS. After centrifugation at 1000 g for 15 min 
at room temperature (Figure 1A), the cell pellet was resuspended in cytotrophoblast culture 
medium, which was high glucose DMEM (Dulbecco’s Modified Eagle’s Medium; Sigma-
Aldrich) supplemented with 10 % FCS and 1 % penicillin-streptomycin-neomycin (Sigma-
Aldrich). To remove residual tissue fragments, the suspension was filtered through a 100 µm 
nylon cell strainer. Afterwards the suspension was centrifuged at 1000 g for 10 min, 
resuspended in CMF Hank’s (Ca/Mg-free 1x HBSS) and layered carefully over two Percoll 
gradients (Sigma-Aldrich) ranging from 70 % to 5 % (each layer 5 % lower than the last). 
Gradients were centrifuged at 1200 g for 20 min at room temperature in a swinging bucket 
rotor without brake. In a 50 mL tube the cytotrophoblasts could be found between the 15 and 
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30 mL mark corresponding to a density between 1.048 and 1.060 g/cm3, while red blood cells 
were in the pellet, cell debris above and lymphocytes underneath the cytotrophoblasts 
(Figure 1B). Cytotrophoblast cells were collected, diluted in cytotrophoblast culture medium 
and centrifuged at 1000 g for 5 min. To increase the purity, immunomagnetic purification was 
performed. To label the non-cytotrophoblast cells, the suspension was incubated for 10 min at 
4 °C with 40 µg/mL mouse anti-human HLA-ABC antibody (Biolegend) in cell separation 
buffer (CSB) consisting of Ca/Mg-free PBS containing 0.5 % bovine serum albumin (BSA; 
Sigma-Aldrich) and 2 mM EDTA (Sigma-Aldrich). After washing the cells twice with CSB, 
MACS® goat anti-mouse IgG MicroBeads (Miltenyi Biotec) were added. Following the 15 min 
incubation period at 4 °C, the cell suspension was washed once with CSB and applied onto a 
previously prepared MS+ separation column in a MiniMACS magnet system (Miltenyi 
Biotec). The effluent containing the unlabeled cytotrophoblasts was collected, centrifuged at 
400 g for 5 min and resuspended in cytotrophoblast culture medium. Subsequently, residual red 
blood cells were removed after 5 min incubation at 4 °C in RBC lysis buffer (Sigma-Aldrich). 
Lysis was stopped with cytotrophoblast culture medium. The yield of isolated primary 
cytotrophoblast cells was about 3 x 107 cells per 50 g tissue. Purity was tested by flow 
cytometry or immunocytochemistry. Cells not used for the purity assays were diluted in 
freezing medium containing 10 % dimethylsulfoxide (DMSO) (Sigma-Aldrich) as well as 
50 % FCS in PBS and stored in liquid nitrogen until use.    
 
 
Figure 1: Isolation of primary human cytotrophoblasts. (A) Cells after tissue digestion and centrifugation with 
FCS. Red blood cells (RBC) are found at the bottom of the pellet and the upper white part contains 
cytotrophoblast cells. (B) Cytotrophoblasts are found around the 20 mL mark after centrifugation in a Percoll 
gradient. RBCs and polymorphonuclear cells (PMN) accumulated in the pellet at the bottom.    
 
3. Results - PART IV 
 
112 
 
Flow cytometry. Approximately 2 x 106 cells were used for each sample. After 
permeabilization with 4 % paraformaldehyde (PFA; Sigma-Aldrich) and 0.2 % Triton X-100 
(Sigma-Aldrich) for 10 min at room temperature, cells were blocked with 5 % goat serum 
(Sigma-Aldrich) for 30 min at room temperature and either stained with mouse IgG1κ (1:1000; 
Sigma-Aldrich) or mouse anti-human cytokeratin-7 (CK-7, 1:200; Dako) diluted with 0.5 % 
BSA in PBS. After washing with PBS all samples were labeled with the secondary Alexa 488 
goat anti-mouse antibody (1:400; Molecular Probes, Invitrogen). Before FACS (fluorescence-
activated cell sorting) analysis using a Partec CyFlow® Space instrument (Sysmex), propidium 
iodide (1:100; BD Pharmingen) was added in order to allow discrimination between cells and 
tissue debris. 
Immunocytochemistry. Primary human cytotrophoblasts before and after immunopurification 
as well as non-cytotrophoblast cells recovered from the MACS® column were seeded in high 
glucose DMEM (Sigma-Aldrich) supplemented with 10 % FCS (Lonza), 1 % penicillin-
streptomycin-neomycin (Sigma-Aldrich) and 10 ng/mL human epithelial growth factor (EGF, 
PeproTech) on a glass coverslip in a 24-well plate (106 cells/ well). After 2 days of culture, 
cells were fixed with 4 % PFA and 0.2 % Triton X-100 for 10 min and blocked with  
5 % goat serum for 1 hour at room temperature. Primary antibodies mouse anti-human CK-7 
(1:200; Dako) and guinea pig anti-human vimentin (1:200; Progen) were diluted in 0.5 % BSA 
in PBS and applied for 1 hour at room temperature. After three washing steps with PBS 
incubation with the secondary antibodies goat anti-mouse Alexa 546 (1:400; Molecular Probes, 
Invitrogen) and goat anti-guinea pig Alexa 488 (1:400; Molecular Probes, Invitrogen) as well 
as DAPI (1:1000; Sigma-Aldrich) for 1 hour at room temperature followed. Afterwards 
coverslips were mounted with Mowiol (Sigma-Aldrich) on a glass slide and air-dried. Cells 
were visualized in a fluorescence microscope (Axioplan 2; Carl Zeiss MicroImaging GmbH). 
Optimization of cell culture conditions for primary human cytotrophoblasts. Primary 
cytotrophoblasts were cultured in high glucose DMEM (Sigma-Aldrich) supplemented with 
10 % FCS (Lonza), 1 % penicillin-streptomycin-neomycin (Sigma-Aldrich) and 10 ng/mL 
human epithelial growth factor (EGF, PeproTech). Cells were grown in 24-well (106 cells/well) 
or 96-well (105 cells/well) plates coated either with rat collagen type I (BD Bioscience) or 
human collagen type IV (Sigma-Aldrich) at 37 °C and 5 % CO2. Medium was exchanged daily. 
Cell growth was assessed by DNA quantification (Hoechst assay) and light microscopy. 
DNA quantification (Hoechst assay) in primary human cytotrophoblasts. 105 primary 
cytotrophoblast per well were seeded in a 96-well plate and cultured under different conditions. 
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After 1, 2, 3 and 4 days cells were washed twice with PBS and incubated with DD (double 
distilled) water for 10 min. Hoechst 33258 solution (Sigma-Aldrich) was added to the cell 
lysates and after 1 hour incubation in the dark on a shaker (200 rpm), fluorescence was 
measured in an FLx800 fluorescence microplate reader (BioTek Instruments) at an excitation 
wavelength of 350 nm and an emission wavelength of 460 nm. A DNA standard was used to 
calculate the DNA amount. The fluorochrome contained in the Hoechst 33258 solution binds 
specifically to DNA and this interaction increases fluorescence emission at 460 nm. 
Fluorescence intensity is directly proportional to DNA content which in turn is proportional to 
the cell number. 
MTS viability assay. The in vitro cytotoxicity of the different NMs was tested using the MTS 
viability assay. Of note, MTS working solution contains the MTS reagent and phenazine 
ethosulfate (PES), an electron-coupling compound. PES penetrates through the cell membrane 
and is reduced by mitochondrial enzymes, which are only active in living cells. Reduced PES 
can leave the cells and converts the MTS to its formazan product, which can be quantified by 
absorbance measurement at 490 nm. To perform this assay, BeWo cells were seeded in a 96-
well plate (8000 cells per well) 24 hours before treatment. 48 hours before treatment primary 
human cytotrophoblasts were seeded in a 96-well plate coated with rat collagen I (4 x 104 cells 
per well) to allow a spontaneous syncytialization of the cells, which occurs after 1 - 2 days. 
Different concentrations of ENMs diluted in high glucose DMEM supplemented with 10 % 
FCS, 1 % penicillin-streptomycin-neomycin and 10 ng/mL human EGF for primary 
trophoblasts or in Ham´s F-12K medium supplemented with 1 % penicillin-streptomycin-
neomycin and 10 % FCS for BeWo cells were applied. As negative control, cells without 
treatment were used and as positive control 1, 10, 100 and 1000 µM CdSO4 was applied. After 
3 or 24 hours of incubation at 37 °C and 5 % CO2, an MTS assay (CellTiter96® AQueous One 
Solution Cell Proliferation Assay; Promega) was performed according to the manufacturer’s 
instructions. The MTS working solution was produced using phenol red free DMEM (Gibco, 
Life Technologies) with 5 % FCS for primary trophoblasts or phenol red free DMEM/F12 
Ham (Sigma-Aldrich) supplemented with 5 % FCS for BeWo cells. Optical density (OD) was 
measured at 490 nm in an EL800 microplate reader (BioTek Instruments). Blank samples 
containing no cells but treated in the same way with ENMs were run with each assay. Values 
were corrected using these blanks and results were presented as mean percentage of the 
untreated control from three independent experiments.  
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ENM interference in the MTS assay. ENM interference with the MTS assay was evaluated in 
a cell-free set-up. Phenol red free DMEM/F12 Ham cell culture medium alone, medium with 
MTS working solution or medium with formazan (addition of 1 mM Na2SO3 to MTS working 
solution resulted in MTS reduction to formazan) was added to the ENM dilutions. Absorbance 
was measured after 1 hour at 37 °C and 5 % CO2 in an EL800 microplate reader (BioTek 
Instruments) at 490 nm. 
Determination of ROS by DCF assay. The formation of reactive oxygen species (ROS) was 
detected by the 2’,7’-dichlorofluorescein (DCF) assay. 2’,7’-dichlorodihydrofluorescein-
diacetate (H2DCF-DA; Molecular Probes, Invitrogen) enters the cells and is cleaved in H2DCF 
by intracellular esterases. H2DCF can be converted in the highly fluorescent DCF by oxidation 
through ROS. 24 hours before assay performance BeWo cells were seeded in a 96-well plate 
(2 x 104 cells per well). The day after, cells were incubated with 50 µM H2DCF-DA in HBSS 
(1 g/L D-glucose, 185 mg/L CaCl2, 400 mg/L KCl, 60 mg/L KH2PO4, 100 mg/L MgCl2, 
100 mg/L MgSO4, 8 g/L NaCl, 350 mg/L NaHCO3, 60 mg/L Na2HPO4) for 60 min at 37 °C 
and 5 % CO2. After washing twice with HBSS, cells were exposed to the respective ENM 
dilutions (diluted in HBSS) or to 50 µM 3-Morpholinosydnonimine (Sin-1; Sigma-Aldrich) 
which is a nitric oxide donor and served as positive control. Fluorescence was measured after 
2 hours using an FLx800 fluorescence microplate reader (BioTek Instruments) at an excitation 
wavelength of 485 nm and an emission wavelength of 528 nm. All results were blank-corrected 
and normalized to untreated cells. To assess the intrinsic potential of the NMs to induce ROS 
without cellular contribution, cell-free control wells with 50 µM H2DCF were run with every 
cell-based assay. 
ENM interference in the DCF assay. ENM interference with the DCF assay was evaluated in 
a cell-free set-up. DD water or fluorescent DCF (Sigma-Aldrich) at a concentration of 2.5 µM 
was added to the ENM dilutions. Fluorescence intensities were measured after 2 hours at 37 °C 
and 5 % CO2 in an FLx800 fluorescence microplate reader (BioTek Instruments). The 
measured intrinsic fluorescence intensities of the ENMs showed a slight concentration 
dependent increase and were therefore subtracted from the fluorescence intensities determined 
after incubation with DCF as well as normalized to the untreated control. The resulting values 
illustrate the quenching effect of the ENMs on DCF fluorescence. 
Hormone secretion. 24 hours before treatment BeWo cells were seeded in a 24-well plate with 
105 cells per well for 6 hours and 5 x 104 cells per well for 24 hours. Cells were stimulated with 
different concentrations of Phorbol-12-myristat-13-acetat (PMA, Sigma-Aldrich) or forskolin 
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(Sigma-Aldrich). In addition, appropriate solvent controls were used (DMSO for PMA and 
ethanol for forskolin).  Supernatants were collected after 6 and 24 hours and stored at -80 °C 
until use. Levels of the placental hormones human chorionic gonadotropin (hCG) and leptin 
were determined by enzyme-linked immunosorbent assay (ELISA) as described elsewhere 
(Malek et al., 1997, Malek et al., 2001). Hormone levels induced in the solvent controls were 
similar to the untreated control and therefore negligible.   
Cytokine assays. 24 hours before treatment BeWo cells were seeded in a 24-well plate 
(5 x 104 cells per well). Cells were stimulated with different concentrations of Phorbol-12-
myristat-13-acetat (PMA), tumor necrosis factor alpha (TNFα, AdipoGen), lipopolysaccharide 
(LPS, Sigma-Aldrich) or interleukin-1 beta (IL-1β, eBioscience). In addition, appropriate 
solvent controls were used (DMSO for PMA and 0.5 % BSA for TNF-α and IL-1β).  
Supernatants were collected after 24 hours and stored at -80 °C until use. IL-6, IL-8 and TNF-α 
levels were determined by ELISA using commercial ELISA Kits (human IL-8 and TNF-α 
ELISA Ready-SET-Go from eBioscience and human IL-6 DuoSet ELISA from R&D) 
according to the manufacturer’s instructions. Cytokine levels induced in the solvent controls 
were similar to the untreated control and therefore negligible. 
Statistical analysis. Data are shown as mean ± standard deviation (SD) from three independent 
experiments. One-way analysis of variance (ANOVA) with Bonferroni test was performed 
using GraphPad Prism software, version 6 (GraphPad Software). A p value below 0.05 was 
considered to be statistical significant. 
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Results and Discussion 
 
Isolation of primary human cytotrophoblasts and optimization of culture conditions 
Primary human cytotrophoblasts were isolated from human term placentas. After tissue 
digestion, cell separation on a Percoll gradient (Figure 1) and immunopurification, purity of the 
cells was tested via immunocytochemistry and/or flow cytometric analysis (Figure 2 and 3). 
Cytokeratin-7 (CK-7) served as a specific marker for cytotrophoblast cells. Placental 
trophoblast cells have no HLA class I antigen on their surface in order to avoid rejection of the 
fetal placental tissue by the immune system of the mother. Therefore, immunopurification with 
magnetic beads against the HLA class I antigen was used to increase the purity of the 
cytotrophoblast cells. Epifluorescence images after 5 days of culture clearly demonstrated a 
contamination with elongated mesenchymal cells in the samples without immunopurification 
(Figure 2A). In contrast, primary cytotrophoblast cells after immunoprurification and 3 days of 
culture fused spontaneously to build several small multinucleated syncytia (Figure 2B). Flow 
cytometric analysis of the cytotrophoblasts from the same isolation directly after 
immunopurification also showed a high percentage of CK-7 positive cells (96.13 % CK-7 
positive cells; Figure 2D). However, the amount of CK-7 positive cells varied intensely 
between individual isolations and placentas. Flow cytometry analysis from another isolation 
did not show a significant difference in CK-7 positive cells before and after 
immunopurification (68.89 % versus 72.51 % CK-7 positive cells; Figure 3).  Indeed, more 
isolations from different placentae are required to verify if the immunopurification is 
improving the purity of the cytotrophoblasts. Moreover, purity may be further increased during 
cell culture if the conditions favor specifically the growth of primary human cytotrophoblasts 
(e.g. contaminating non-adherent immune cells will be lost). For all further assays primary 
human cytotrophoblasts solely from isolations with at least 90 % purity were used. To optimize 
the culture conditions and support syncytialization of primary cytotrophoblasts, different plate 
coatings with rat or human collagen were applied. Besides visual control by light microscopy, 
the DNA amount, as indicator for the cell number, was quantified. DNA quantity is the only 
measurable variable, which remains stable after fusion of the cells (total number of nuclei in 
the cell culture plate stays the same, while the volume of the cytoplasm and protein production 
can be altered). After one day of culture there was no difference between these conditions, 
whereas after 2 days the cell number in the samples with collagen coating (rat and human) was 
increased compared to the samples without coating (Figure 4). There was no significant 
difference between rat and human collagen coating. Moreover, cells survival and growth was 
3. Results - PART IV 
 
 
117 
impaired on collagen coated plates without addition of EGF (Figure 4) indicating that EGF is 
also a major determinant of cell proliferation and/or survival, which also has been described in 
the literature (Maruo et al., 1987, Humphrey et al., 2008, Morrish et al., 1997). After 3 days 
there was no further increase in cell number and after 4 days even a slight decline due to their 
limited viability in culture (Figure 4). Of note, a massive proliferation of the isolated primary 
human cytotrophoblasts after syncytialization (occurs after 24 – 48 hours of culture) was not 
expected because trophoblast fusion and terminal differentiation leads to a cell cycle arrest 
(Depoix et al., 2013). Based on our findings primary cytotrophoblast cells could be optimally 
cultured on rat collagen coated plates in presence of EGF. However, further studies with cells 
from several independent isolates have to confirm this finding.  
 
 
Figure 2: Assessment of the purity of the isolated primary human cytotrophoblasts by two different methods. (A – 
C) Epifluorescence images of isolated primary cytotrophoblasts before (A) and after (B) immunopurification as 
well as HLA class I positive cells from the column (C) after 3 - 5 days of culture. Cells were stained for the 
cytoskeletal proteins cytokeratin-7 (CK-7; red) as a marker for trophoblasts and vimentin (green) as a marker for 
mesenchymal cells. Nuclei were stained with DAPI (blue). (D) Flow cytometric analysis of the isolated primary 
cytotrophoblasts after immunopurification. Left panel: Cells in the forward (FSC) and side (SSC) scatter. Middle 
panel: Propidium iodide stained all cell populations and gate A was set to exclude all residual debris from the 
tissue digestion. Right panel: Isotype control and cytokeratin-7 (CK-7) stained cells in gate A. 
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Figure 3: Flow cytometric analysis of the purity of isolated primary cytotrophoblasts before (A) and after (B) 
immunopurification. Left panel: Cells in the forward (FSC) and side (SSC) scatter. Middle panel: Propidium 
iodide stained all cell populations and gate A was set to exclude all residual debris from the tissue digestion. Right 
panel: Isotype control and cytokeratin-7 (CK-7) stained cells in gate A. 
 
 
Figure 4: (A) Quantification of the DNA amount from isolated primary human cytotrophoblast cells after 1,2,3 or 
4 days of culture with or without (w/o) daily addition of 10 ng/mL EGF. Plates were either coated with rat or 
human collagen or used without coating. On day 0 primary cytotrophoblasts were thawed and 105 cells/well were 
seeded (96-well plate). Medium was exchanged every day in all conditions. To assess the DNA amount 
fluorescent Hoechst 33258 was used after lysis of the cells. Displayed results are from one experiment. (B) Light 
microscopic images of isolated primary human cytotrophoblasts after 2 and 4 days of culture under the indicated 
culture conditions. 
3. Results - PART IV 
 
 
119 
Acute toxicity of ENMs on BeWo and primary human cytotrophoblast cells 
If BeWo cells and primary human cytotrophoblasts possess a different sensitivity regarding 
cytotoxicity to ENMs was investigated in the MTS assay. All three differently modified gold 
particles did not induce cytotoxicity in BeWo cells even after 24 hours incubation (Figure 5). 
However, for the amine-modified PS beads and MWCNTs a significant time- and dose-
dependent reduction in the number of viable cells was observed (Figure 5). ENMs may bind to 
the cell culture plate and generate an absorbance signal by themselves, directly reduce the MTS 
reagent or interfere with the formazan product. Therefore, the potential interference with the 
assay was examined in a cell-free control experiment. For the positive and neutral gold 
particles a concentration-dependent intrinsic absorbance, but no interference with the formazan 
product and no reactivity with the MTS reagent was observed. This is displayed in the left 
panel of Figure 6, where the slopes of all three curves are similar. Consequently, the OD values 
from the cell free controls, which were performed simultaneously with the cell-based assay, 
can be subtracted as blank to totally correct for this intrinsic absorbance of the positive and 
neutral gold particles at higher concentrations. The negative gold particles (200 µg/mL) led to a 
slight increase in formazan absorbance and the amine-modified PS beads (≥ 100 µg/mL) as 
well as the MWCNTs (≥ 25 µg/mL) caused a significant decline in formazan absorbance at 
higher concentrations (Figure 6). Altered absorbance values for formazan would either disguise 
a cytotoxic effect in the case of elevated values or display a false positive result if ENMs itself 
induce a decrease of absorbance values. Subsequently, a reliable cytotoxicity evaluation by the 
MTS assay is only possible for concentrations where no interference occurred. Hence, the 
negative gold particles could be considered non-cytotoxic up to a concentration of 100 µg/mL 
after 24 hours of exposure (Figure 5). Amine-modified PS beads demonstrated a significant 
decrease in enzyme activity already at a concentration of 50 µg/mL after 3 hours and 25 µg/mL 
after 24 hours, which are both below the threshold where interference arises (Figure 5 and 6). 
After 24 hours of exposure, MWCNTs illustrated also a trend for decreased cell viability at 
lower concentrations of 6.25 and 12.5 µg/mL indicating a clear cytotoxic effect of MWCNTs 
on BeWo cells (Figure 5). Cadmium sulfate (CdSO4) induces cell death and was used as 
positive control in the MTS assay with BeWo cells and primary human cytotrophoblasts. After 
3 hours primary human cytotrophoblasts demonstrated already a minor decline in cellular 
activity at 100 µM CdSO4, while BeWo cells showed no toxic effect at the same concentration 
(Figure 5 and 7). These results indicate that primary cytotrophoblasts are slightly more 
sensitive to CdSO4 compared to BeWo cells. However, due to the limited availability of 
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primary cytotrophoblasts these findings have to be elucidated in further experiments using 
CdSO4 as well as ENMs, which already showed a reduction in BeWo cell viability.  
 
 
 
Figure 5: Cell viability of BeWo cells was assessed by MTS assay 3 (A) and 24 hours (B) after treatment with the 
indicated ENM concentrations. CdSO4 is a known cell death inducer and served as positive control. Optical 
density was measured at 490 nm and values were blank-corrected as well as normalized to the untreated samples. 
The red dashed line indicates the level of the untreated samples at 100 %. Data is expressed as mean ± SD of three 
independent experiments. (*) p < 0.05 compared to the respective solvent control (0 µg/mL) 
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Figure 6: Potential interference of ENMs with the MTS assay was assessed by performing a cell-free control 
experiment. Different concentrations of amine-modified PS beads (A), MWCNTs (B) as well as positive (C), 
neutral (D) and negative (E) gold nanoparticles (NPs) were added to medium alone, MTS working solution or 
formazan. The left panel shows the unprocessed OD values of all three conditions. In the right panel OD values 
were corrected using the OD values resulting from incubation with medium alone as blank. Data represents mean 
± SD from two technical replicates of one experiment. 
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Figure 7: Cell viability of primary human cytotrophoblast cells was assessed by MTS assay 3 and 24 hours after 
treatment with CdSO4. Optical density was measured at 490 nm and values are blank-corrected as well as 
normalized to the untreated samples. The red dashed line indicates the level of the untreated samples at 100 %. 
Displayed results represent one preliminary experiment. 
 
The formation of ROS could be one possible cause for reduced cell viability after ENM 
exposure (Schins and Knaapen, 2007, Nel et al., 2006). If elevated ROS levels exceed the 
protective anti-oxidant defense mechanisms of a cell, oxidative stress will emerge. 
Consequently, lipids, proteins and DNA will be damaged which leads to genotoxicity, 
inflammation or cell death (Schins and Knaapen, 2007). ROS formation in BeWo cells was 
investigated by using the DCF assay. After 2 hours of exposure, significant amounts of ROS 
were only detected for MWCNTs (Figure 8A). However, cell-free control experiments showed 
also a dose-dependent intrinsic reactivity of MWCNTs to induce ROS formation (Figure 8B). 
This indicates that the ROS formation seen in BeWo cells is not solely due to cellular activity, 
but may also be a consequence of direct interactions between the MWCNTs and the H2DCF. 
Interestingly, at higher MWCNT concentrations (> 50 µg/mL) the ROS level in BeWo cells 
declined (Figure 8A). Interference testing revealed that increasing concentrations of MWCNTs 
and gold particles extensively quenched the fluorescence signal from the DCF (Figure 8C), 
which has been also described for other ENMs (Kroll et al., 2009, Bachmatiuk et al., 2013). Of 
note, the amine-modified PS beads quenched the DCF fluorescence signal in a dose-dependent 
manner up to a concentration of 25 µg/mL, but the signal rose again with a further increase in 
PS concentration (50 – 200 µg/mL). PS beads might interact with DCF in a way that leads to 
an altered absorbance spectrum, which has to be evaluated in further studies. The ROS 
production in primary human cytotrophoblast cells could not be assessed yet, but additional 
experiments will follow in order to show if there is a difference in ROS formation between 
both cell types. 
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ENMs can also lead to inflammatory responses of cells (Nel et al., 2006). Therefore, the 
secretion of the (pro-) inflammatory cytokines IL-8, IL-6 and TNF-α by BeWo cells was 
examined. Several studies show that BeWo cells as well as placental cells are able to produce 
these cytokines upon stimulation in vitro and ex vivo (Bennett et al., 1996, Fujisawa et al., 
2000, Shimoya et al., 1999, Tsukihara et al., 2004, Wagner et al., 2000). We observed no IL-8 
production by BeWo cells after stimulation with TNF-α, PMA, LPS and IL-1β, but secretion of 
IL-6 upon stimulation with TNF-α, PMA and IL-1β (Figure 9B). Stable and significant TNF-α 
production was induced solely by IL-1β stimulation (Figure 9A). Further experiments are in 
progress to elucidate if BeWo cells and primary human cytotrophoblasts have a distinct 
capability and sensitivity to produce these cytokines upon stimulation with the known 
stimulants (TNF-α, PMA, LPS, IL-1β) or in response to ENMs.  
Genotoxicity is usually also investigated if ENM-cell interactions are evaluated. This might be 
also considered in our model, but the feasibility of genotoxicity assays for primary 
cytotrophoblasts with limited in vitro viability has to be assessed carefully. For example it is 
not possible to detach primary human cytotrophoblasts from cell culture plates without 
destroying the syncytia, which is necessary for many assays such as the comet assay.  
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Figure 8: Formation of ROS in BeWo cells (A) and intrinsic reactivity of the ENMs under cell-free conditions 
(B) was determined after 2 hours incubation with the indicated ENM concentrations by using the DCF assay. Sin-
1 (50 µM) served as positive control. 0 µg/mL corresponds to the respective solvent control (DD water or Pluronic 
F127). Data is expressed as mean ± SD of two independent experiments. (C) Quenching effects of the ENMs was 
determined by incubating DCF with the indicated concentrations of ENMs for 2 hours. Fluorescence values of all 
three set-ups are blank-corrected and normalized to the untreated control. The red dashed line indicates the level 
of the untreated samples at 100 %. Data represents mean ± SD from three technical replicates of one experiment. 
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Impact of ENMs on BeWo cells’ functionality (subacute toxicity) 
The acute toxicity reactions described in the previous part are similar in many cell types. But to 
validate an advanced in vitro model for the placenta, also cell type-specific readouts are 
required. Therefore, assays to investigate the expression and activity of efflux transport 
proteins such as breast cancer resistance protein (BCRP) and p-glycoprotein (P-gp) as well as 
of placental enzymes like the cytochrome P450 family will be developed in order to reveal 
differences between Bewo cells and primary human cytotrophoblasts regarding these placenta-
specific functions after exposure to ENMs. In a first step, we already established an ELISA to 
analyze the secretion of the placental hormones leptin and hCG in BeWo cells. To stimulate 
hormone secretion, forskolin and PMA were applied. Forskolin alone or in combination with 
PMA are usually used to induce syncytialization and differentiation of BeWo cells, which also 
leads to a higher hCG production (Omata et al., 2013). While a significant production of hCG 
was achieved after stimulation for 24 hours with forskolin, Leptin levels remained low and 
showed a high variance between the experiments (Figure 9C, D). 
 
 
Figure 9: (A + B) BeWo cells were incubated with different concentrations of PMA, LPS, IL-1β and TNF-α for 
24 hours and induction of inflammatory cytokines TNF-α (A) and IL-6 (B) was measured by ELISA. Data is 
expressed as mean ± SD of two independent experiments. (C + D) BeWo cells were treated with the indicated 
concentrations of PMA and forskolin to stimulate Leptin (C) and hCG (D) production which was determined after 
6 or 24 hours by ELISA. Data represents mean± SD of three independent experiments. 
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Uptake of ENMs in BeWo cells 
Besides the influence of ENMs on cellular functions, the uptake of ENMs to BeWo and 
primary human cytotrophoblast cells will be investigated I order to determine if there is a 
significant difference in intracellular uptake of ENMs between these cells. A first preliminary 
experiment was performed by exposing BeWo cells to positive, neutral and negative gold 
particles (100 µg/mL). After 24 hours of exposure, cells were analyzed by light microscopy. 
Interestingly, large amounts of the positive gold particles seemed to be taken up by the BeWo 
cells, whereas the neutral and negative gold particles were rarely co-located with the cells 
(Figure 10). This finding indicates that the surface charge of these gold particles may 
determine their uptake in BeWo cells. Studies with other ENMs and at other barriers also 
showed a surface charge dependent uptake of several ENMs (Choi et al., 2010, Schleh et al., 
2012, Tian et al., 2009). Of course, this is only a preliminary as well as qualitative evaluation 
and further quantitative studies are required. Furthermore, investigations using fluorescent 
ENMs and analysis by confocal laser scanning microscopy (CLSM) are essential to proof if the 
ENMs are indeed located inside the cells or just adsorbed to the membrane. 
 
 
Figure 10: Light microscopic images of BeWo cells after 24 hours treatment with 100 µg/mL positive (A), neutral 
(B) or negative (C) gold particles. Red arrows indicate BeWo cells. 
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Conclusions 
 
Overall, the isolation of primary human cytotrophoblast cells requires more time and is more 
expensive compared to BeWo cell cultures, which are easy to handle. The low yield of such 
primary cell isolations as well as their limited viability in culture further constrain their 
applicability for high throughput screenings of ENM-cell interactions. One possible solution 
would be to use BeWo cells for a first screening of a broad variety of ENMs. Then, based on 
the respective findings interesting ENMs are selected and their cellular responses further 
assessed in primary human cytotrophoblasts. However, subacute toxicity of ENM meaning 
effects on cell functionality might be better reflected in the physiologically more relevant 
primary cells compared to the tumor-derived BeWo cells. Therefore, another solution would be 
to implement primary human cytotrophoblasts in advanced in vitro models, which do not need 
a huge number of cells. For example three-dimensional microtissues generated by hanging 
drop technology, consist of fibroblasts, which are surrounded by one layer of a few hundred 
trophoblast cells. For the assessment of ENM transport, microfluidic chips would be also 
interesting and are anticipated for small volumes and cell numbers. Nevertheless, primary 
human cells require more sophisticated culture conditions and are difficult to standardize 
compared to established cell lines (Gstraunthaler and Hartung, 2002, Coecke et al., 2005). 
Whether this concerns also primary cytotrophoblasts remains to be determined in further 
studies.       
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4. FINAL DISCUSSION AND OUTLOOK 
 
4.1 Final Discussion 
 
Evaluation of ENM translocation across biological barriers is essential for ENM risk 
assessment. Thus, it is not surprising that this is an intensive field of research. My PhD thesis 
was focused on the human placenta as an important internal biological barrier using 
fluorescently labeled polystyrene beads as model particles. The results of this work illustrate 
that ENM transport studies in a physiological relevant model such as the ex vivo placental 
perfusion can provide significant information about the relationship of ENM properties and 
placental transfer as well as transport mechanisms (see chapter 3, part II). Placental transfer of 
polystyrene particles occurred not via passive diffusion, but rather via energy-dependent 
mechanisms. This main result of my work is in concert with the findings from studies at other 
biological barriers. For the air-blood and the blood-brain barrier, active transport mechanisms 
such as endocytosis are also proposed as potential transport pathways for ENMs 
(Brandenberger et al., 2010, Kreuter, 2014, Kreyling et al., 2014, Muhlfeld et al., 2008, 
Thorley et al., 2014). Additionally, placental translocation of polystyrene beads was found to 
be also dependent on their surface modification, whereas the transfer of plain particles was 
significantly higher than for carboxylate-modified beads (see chapter 3, part II). These findings 
indicate a potential impact of the protein corona, which is formed around ENMs immediately 
after contact with biological fluids and can significantly alter ENMs biokinetics (Pietroiusti et 
al., 2013, Lundqvist et al., 2008, Ehrenberg et al., 2009). It has to be considered that protein 
expression in the tissue and protein composition of the blood vary between the fetus and the 
mother suggesting that kinetics and cellular responses to ENMs might be completely different 
during prenatal development compared to the cellular reactions in adult tissue (Juch et al., 
2013, Malek et al., 2001, Linnemann et al., 2000). Of course, further studies using ENMs with 
different chemistry and surface modifications are needed to corroborate this hypothesis and to 
build the basis for the development of nanomedical applications of the third generation, which 
will be specifically designed with an enhanced ability to cross biological barriers.   
 
There is general consent that the physicochemical properties of ENMs mainly determine 
cellular uptake, biodistribution and toxicity (Nel et al., 2009, Pietroiusti et al., 2013). Though, 
many studies show controversial results and it is still debated, which ENM characteristic leads 
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to which cellular response (Johnston et al., 2013, Warheit, 2008). Major problems regarding 
this issue are insufficient description of the material characterization, preparation procedures of 
ENM dispersions and selection of physiological relevant concentrations, mode of 
administration as well as appropriate models (Krug, 2014).  
My thesis demonstrates some of these challenges such as identification of a relevant model and 
pitfalls during ENM evaluation (see chapter 3, part I, III, IV). Although, many ENM are 
commercially available and are delivered with some information about their properties, an 
extensive particle characterization in the context of the used biological test system (relevant 
media) is inevitable and comprises analysis of the size distribution, surface modifications, 
particle agglomeration, particle stability, potential dye elution as well as degree of 
contamination with residual manufacturing components or endotoxins (Crist et al., 2013). 
Furthermore, the testing strategy is just as important as ENM characterization to draw valid 
conclusions from nanotoxicological studies. To obtain comparable and reliable results 
validated and standardized methods with a high traceability of the results, an implemented 
quality control system and an appropriate consideration of measurement uncertainties are 
required (Hirsch et al., 2011). Additionally, intrinsic controls, reference standards, at least two 
independent measurement techniques per end point, comparable dose metrics and careful 
evaluation of ENM interference with the assay should be implemented (Hirsch et al., 2011). 
Especially the assessment of dosimetry is essential for nanotoxicological in vitro studies. Often 
the colloid stability of ENMs is not given any more after contact with cell culture media. This 
leads to actual cellular doses, which can be different from the initially applied ENM 
concentrations and may cause misinterpretations of the data about ENM uptake and toxicity 
(Teeguarden et al., 2007, DeLoid et al., 2014). Finally, increasing the understanding of nano-
bio interactions requires a systematic and multidisciplinary approach. Overall, the field of 
toxicology research in general is moving from phenomenological towards more mechanistic 
assessment including high throughput and high content screening of substances for potential 
toxicity and quantitative analysis of the structure-activity relationships (QSAR). The QSAR 
regression models in combination with computational biology can be used to develop 
predictive toxicology approaches in order to reduce traditional animal testing and a safer 
design of chemicals. Moreover, new projects emerge and aim to map toxicological pathways of 
chemicals instead of simple cytotoxicity testing. Similar concepts have to be implemented in 
the risk assessment of ENMs (Nel, 2013). The elucidation of toxicological pathways using 
genomics and proteomics approaches may be as important as to clarify the cellular transport 
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mechanisms used by ENMs. For such a strategy the selection of a relevant biological model is 
crucial. 
 
Besides the animal models, which are not suitable for human assessment due to the interspecies 
differences in placental structure, there are two models used frequently to study placental 
transfer of ENMs: the BeWo transwell system and the ex vivo human placental perfusion 
model (Cartwright et al., 2012, Sonnegaard Poulsen et al., 2013, Wick et al., 2010). Placental 
transfer of ENMs in vitro across a BeWo cell layer is significantly lower and the equilibration 
time longer compared to the ex vivo human perfusion model (Poulsen et al., 2009, Sonnegaard 
Poulsen et al., 2013). This is mainly due to the absence of both, flow as well as an appropriate 
hydrostatic pressure on the fetal side. However, the BeWo cell model is easier to handle due to 
the simple experimental set-up and also longer exposure times (up to several days) are feasible, 
whereas the ex vivo perfusion is technically far more challenging and the duration of perfusion 
is limited to a few hours because of the starting tissue degradation (Di Santo et al., 2003, 
Mathiesen and Knudsen, 2013, Poulsen et al., 2009). In addition, many factors such as 
maternal health, placental disruptions caused during delivery and the ischemic phase after 
delivery contribute to the low success rate (about 20 %) of ex vivo placental perfusions, which 
constrains throughput of the model (Grafmuller et al., 2013, Mathiesen and Knudsen, 2013). 
Furthermore, oxidative stress and cell death during the ischemic phase can influence the 
experimental outcome concerning transfer as well as other cellular responses to ENMs 
(Mathiesen and Knudsen, 2013). But since the placenta has been described as specifically 
tolerant to hypoxia and capable to quickly recover during reperfusion in the laboratory, 
ischemia is not a major problem (Schneider, 2009). BeWo cells are tumor-derived cells and are 
as such genetically homogenous, while human placentae from various individuals have genetic, 
dietary as well as maternal health related differences. The latter could lead to a higher 
variability of the results, but it also reflects the normal variability within the population and 
therefore increases the in vivo relevance of the data obtained by using the ex vivo perfusion 
model. Another disadvantage of the BeWo transwell model is that it lacks the complexity of a 
whole organ. It is known that many cell types especially macrophages in placental as well as in 
decidual tissue (the part of the uterus contributing to placenta formation at the site of 
implantation) play an important role in maintaining maternal immune tolerance against the 
fetus (Cupurdija et al., 2004). Since ENMs have shown to impair immune cell functions, to 
induce production of pro-inflammatory cytokines and to change the activation status of 
macrophages, it has to be evaluated if such reactions may also have an influence on the 
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sensitive immunological balance in the human placenta (Oberdorster et al., 2005, Scherbart et 
al., 2011, Juch et al., 2013). Though for such studies a model including all involved cell types 
would be necessary.  
Furthermore, both models do not account for the changes of placental structure and function 
during gestation. The transfer of immunoglobulins across the human placenta is substantially 
dependent on gestational age (Palmeira et al., 2012). Hence, differences in placental 
toxicodynamics and –kinetics of ENMs between term and early gestation might be also 
possible (Juch et al., 2013, Nikitina et al., 2013). The first trimester is the most critical peroid 
during pregnancy regarding vulnerability of the fetus. Most organs are developed in this time 
and harmful substances with a high placental permeability can induce severe malformations or 
impair placental development leading to placenta related diseases such as gestational diabetes, 
preeclampsia or intrauterine growth restriction (Benirschke, 2012). To protect the fetus from 
exogenous influences during early gestation, the placental barrier is thicker compared to late 
gestation, because of an additional layer of cytotrophoblast cells covering the 
syncytiotrophoblast on the fetal side of the placental villous. Although the increased barrier 
thickness exacerbates placental transfer of ENMs, the toxicity may be even augmented. Sood et 
al. observed an inverse correlation between barrier thickness and toxicity using a co-culture 
model with multiple layers of BeWo cells on the apical side of a transwell insert and 
fibroblasts in the basal chamber. After application of cobalt chromium nanoparticles to the 
apical chamber more DNA damage in the fibroblasts at the basal chamber was detected with 
increasing numbers of BeWo layers and without translocation of the nanoparticles indicating 
an indirect effect mediated by cytokine signalling (Sood et al., 2011). Besides the fact that the 
transfer of most substances and pathogens is restricted or even prevented during the first 
trimester, translocation of some natural nanoparticles with a size of 50 – 70 nm such as the 
rubella virus is enhanced and declines with increasing gestational age (Webster, 1998, Galvan-
Ramirez Mde et al., 2014). Thus, a similar phenomenom for ENMs cannot be excluded. 
Another possibility to study the functions of the early placenta is the use of first trimester 
placental tissue explants obtained from elective pregnancy terminations. Although placental 
explants offer a higher degree of tissue complexity compared to transwell models with cell 
lines, they still lack blood flow and real translocation studies are not possible. Nevertheless, 
first trimester placental explants are useful for first investigations of ENM uptake, the 
contribution of distinct transport mechanisms and the cellular responses to ENMs (Juch et al., 
2013, Miller et al., 2005). Moreover, little is known about the contribution of the fetal 
membranes to fetal transfer particularly during early pregnancy. It was demonstrated that 
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dendrimers in the nanoscale are transported across fetal membranes but only in very low 
amounts. These findings indicate that the impact of this mode of transfer is rather small, 
nevertheless it should be considered for the development of nanomedical applications, which 
are administered intravaginally  (Menjoge et al., 2010).  
 
To conclude, it is clear that all models have their limitations and that the selection of the model 
has to be based on the questions which should be answered. Overall, the BeWo transwell 
model is suitable to perform a first initial screening of ENM toxicity and to assess the 
contribution of specific transport mechanisms to ENM transfer, whereas the ex vivo human 
perfusion model is more appropriate to predict the in vivo transfer of ENMs.   
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4.2 Outlook 
 
The statistician George E. P. Box wrote, "essentially, all models are wrong, but some are 
useful". In order to make the placental models more useful for nanotoxicological studies, there 
are efforts to improve those and develop new advanced human in vitro models which allow 
high throughput screenings but also maintain a certain level of the original organ complexity 
(Figure 1). The last part of my thesis already dealt with the isolation and characterization of 
primary human cytotrophoblast cells with the intention to replace the BeWo cells against a 
physiologically more relevant cell type. However, first preliminary experiments demonstrated 
that the yield of such primary cell isolations as well as their viability in culture are limited (see 
chapter 3, part IV) (Depoix et al., 2013). Nevertheless, these cells can be used in models, 
where only few cells are needed. For example is the microfluidics technology anticipated to 
manipulate complex fluids at the submillimeter scale and has already led to the development of 
lab-on-a-chip and organ-on-a-chip approaches (Richter et al., 2011, Sackmann et al., 2014) 
(Figure 1). The major advantage of such a placenta-on-a-chip model are the low amounts of the 
test ENMs and the placental barrier cells required for this method, the controllable flow, which 
could be optimally adjusted to the in vivo situation, and the possibility of high throughput 
screenings. In addition, it is feasible to include more than one cell type into the model and 
further enhance the in vivo relevance. Microfluidics models would be suitable to investigate 
ENM transfer and to identify distinct transport as well as toxicological pathways by using 
specific inhibitors. A second model, in which BeWo cells can be replaced by primary human 
cytotrophoblasts, are the scaffold-free self-organized organoids or microtissues (Astashkina 
and Grainger, 2014, Kelm and Fussenegger, 2004). Three-dimensional microtissues with a core 
of fibroblasts and a trophoblast shell can mimic the structure of the placental villi at term or 
with multiple layers of cytotrophoblasts also at early gestation (Figure 1). ENM uptake into the 
tissue and their respective mechanisms as well as cellular responses to ENMs can be evaluated 
in this model. Of note, the practicability of using primary human cytotrophoblasts in these two 
models has to be analyzed first. Primary cytotrophoblasts do not build a confluent layer as the 
BeWo cells but instead form large aggregates with large intercellular spaces if cultured on 
semipermeable membranes (Liu et al., 1997, Yui et al., 1994). Though, this growth pattern may 
be completely different in a three-dimensional environment as in the microtissues. Another 
approach especially for the elucidation of placental transport is the integration of perfusion 
flow and endothelial cells in the BeWo transwell model (Figure 1). Both of these aspects 
would tremendously increase the physiological relevance of this model, but still preserves the 
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possibility for medium to high throughput screenings and a certain degree of reproducibility. 
After an accurate standardization and validation of the model against the ex vivo perfusion or 
epidemiological data, this co-culture transwell perfusion set-up could provide a powerful 
model to investigate placental transfer of ENMs and to elucidate the mechanisms and cell types 
contributing to this translocation process.  
 
	  
Figure 1: In the upper part the most frequently used placental models, the two-dimensional (2D) BeWo cell 
culture or BeWo transwell system and the ex vivo human placental perfusion model, are displayed. In between are 
some advanced in vitro models, which are currently under development: the three-dimensional (3D) microtissues 
with a fibroblast core and a shell of trophoblast cells e.g. BeWo cells, which are stained with cytokeratin-7 
(yellow), the microfluidic placenta chip (Ertl, 2013) and the perfused transwell with BeWo as well as endothelial 
cells, which both contribute to the placental barrier in this model.   
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Figure 2:	   Scheme summarizing the actions to be taken to further improve the relevance of advanced human in 
vitro models. Reprinted with permission from  (Wick et al., 2014). 	  
Generally, toxicology as well as nanotoxicology is developing towards an evidence-based 
research discipline, which requires new advanced human in vitro models. These models have 
to be standardized and carefully validated in an improved cell culture environment. Adapted 
analytics, application-oriented research and implementation of new technologies will lead to 
models, which support toxicologists in the generation of comparable, reliable and meaningful 
results (Wick et al., 2014) (Figure 2). These advanced human in vitro models will not only 
change the field of nanotoxicology, but will also lead to a better understanding of the placenta 
itself. Placental dysfunctions have been linked to several diseases e.g. cardiovascular diseases 
in the later life of the child (Barker and Thornburg, 2013, Hennington and Alexander, 2013, 
Saade, 2009). Recently, the National Institutes of Health in the United States issued the 
‘Human Placenta Project’ with the aim to increase the knowledge about placental structure, 
development and functions. Monitoring of critical placental functions could help to identify 
high risk pregnancies earlier and detailed data about the mechanisms underlying placental 
abnormalities such as preeclampsia could lead to new therapeutic strategies. Preventive and 
therapeutic interventions will have a major impact on pregnancy outcome as well as children’s 
health (Guttmacher et al., 2014).    
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